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1. Abbreviations 
2-AG 2-arachidonoyl glycerol  
AA Arachidonic acid 
ANOVA Analysis of variance 
BH4 Tetrahydrobiopterin 
BP Blood pressure  
cAMP cyclic Adenosine monophosphate  
cGMP cyclic Guanosine monophosphate 
Cav Voltage operated calcium channel 
CB1 Cannabinoid-1  
CB2 Cannabinoid-2 
CBF Cerebral Blood Flow 
CNS Central nervous system 
CO2 Carbon dioxide 
CoBF Cerebrocortical Blood Flow 
COX Cyclooxygenase  
cpm Cycle per minute 
DAG Diacylglycerol 
EC Endocannabinoid 
EDHF Endothelium-derived hyperpolarizing factor  
ET-1 Endothelin-1  
FAAH Fatty acid amide hydrolase  
FFT Fast Fourier Algorithm  
GMP 3’,5’ guanosine monophosphate 
GPCR G-protein coupled receptors  
GTP Guanosine triphosphate 
H/H Hypoxia and hypercapnia 
HETE Hydroxyeicosatetraenoic acid 
HPETE Hydroperoxyeicosatetraenoic acid 
i.v. Intravenous 
ICP Intracranial pressure 
IKCa Intermediate calcium-activated potassium channel 
IP3 Inositol-1,4,5-trisphosphate 
KIR  Inwardly rectifying K channels 
LARG Leukemia-associated RhoGEF 
LD Laser-Doppler  
LDF Laser-Doppler flux 
L-NAME Nω-nitro-L-arginine methyl ester  
LOX Lipoxygenase 
LPA Lysophosphatidic acid  
LPC 1-O-alkyl-lysophosphatidylcholine 
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LT Leukotriene 
LX Lipoxin 
MAP Mean arterial pressure 
MCA Middle cerebral artery 
MLC Myosin light chain  
MLCK Myosin light chain kinase 
MLCP Myosin light chain phosphatase 
MYPT1 Myosin phosphatase targeting subunit 1 
NADPH Nicotinamide adenine dinucleotide phosphate 
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B 
cells 
NO Nitric oxide 
NOS Nitric oxide synthase 
O2 Oxygen 
PaCO2 Arterial carbon dioxide tension 
PAF Platelet-activating factor  
PaO2 Arterial oxygen tension 
PG Prostaglandin 
PGI2 Prostacyclin  
PKA Protein kinase A  
PKC Protein kinase C  
PKG cyclic GMP-dependent kinase  
PLA2 Phospholipase A2  
PLC Phospholipase C 
PUFA ω-3 polyunsaturated fatty acids  
RhoGEF Rho-specific guanine exchange factors  
RR Respiratory rate 
S1P Sphingosine-1-phosphate  
SAH Subarachnoid hemorrhage 
SEM Standard error of the mean 
SKCa Small calcium-activated potassium channel 
THC Δ9-tetrahydrocannabinol 
TP  Thromboxane  
TRP Transient receptor potential 
TRPV1 Transient receptor potential vanilloid type-1 
TXA2 Thromboxane A2 
UTP Uridine-5'-triphosphate 
WHO World Health Organization 
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2. Introduction 
The occurrence of cerebrovascular diseases, consisting of ischemic-, hemorrhagic stroke 
and subarachnoid hemorrhage, are the fourth leading cause of death in the modern 
world [1]. On average, every 40 seconds someone experiences stroke, and every 4 
minutes it causes death [2]. During stroke, the cerebral blood flow is insufficient thus 
the consequent reduction in oxygen availability (hypoxia) impairs cellular respiration 
and energy production, resulting in the decreased availability of ATP; subsequently, 
ATP-dependent ion pumps, such as the Na
+
/K
+
 ATPase, are unable to maintain the 
physiological transmembrane ion gradients. The rapid accumulation of Ca
2+
, due to 
influx from the extracellular space, results in the activation of lipases, for instance 
phospholipase A2, which contributes to the formation of arachidonic acid metabolites 
[3]. Furthermore, the increased intracellular Ca
2+
 concentration activates, via the Ca
2+
 - 
calmodulin complex, the neuronal and endothelial nitric oxide synthase (NOS); 
resulting in the enhanced production of the potent vasodilatory mediator, nitric oxide 
(NO) [4,5]. The initial burst of NO generation is followed by a gradual exhaustion in the 
enzymatic activity especially in cases associated with hypertension [6,7], traumatic 
brain injury [8] and diabetes mellitus [9], resulting in the decreased bioavailability of 
nitric oxide.  
It has been previously observed that under pathophysiological conditions coupled with 
limited oxygen and NO availability, the vascular reactivity is enhanced [10]; low 
frequency oscillations in the cerebral blood flow appears, described as vasomotion in 
isolated vessels, which phenomenon reportedly precedes the appearance of vasospasm 
[11,12]. 
Hence an improved understanding of the cerebrocortical blood flow regulation is 
essential to successfully treat cerebrovascular diseases and improve the chances of full 
recovery. In the current study, I have investigated the role of arachidonic acid 
metabolites, namely thromboxane A2 (TXA2) and endocannabinoids (EC) in the 
cerebrovascular blood flow regulation.  
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2.1. Cerebrovascular disease 
2.1.1. Definition and pathogenesis of stroke 
Stroke is defined, as “rapidly developing clinical signs of focal (or global) disturbance 
of cerebral function, with symptoms lasting 24 hours or longer or leading to death, with 
no apparent cause other than of vascular origin” [13]. Based on the pathological 
background of stroke, we can distinguish between ischemic and hemorrhagic origin. 
The major cause of ischemic stroke (infarction) is the complete occlusion of large 
cervical and cerebral arteries resulting in infarction of the territory supplied by the 
occluded artery. This can be due to occlusion at the site of a main atherosclerotic lesion 
or to embolism originating from other parts of the arterial system, most frequently, from 
cardiac cavities or valves, or can be due to cardiac rhythm disturbances [14]. 
Hemorrhagic stroke is spontaneous intracerebral bleeding and is mainly due to arteriolar 
hypertensive disease. Other potential risk factors are coagulation disorders, vascular 
malformation within the brain, and diet (such as high alcohol consumption, low blood 
cholesterol concentration, etc. [14]). Subarachnoid hemorrhage (SAH) is mainly due to 
the rupture of aneurysms at the bifurcations of large arteries on the inferior surface of 
the brain. The bleeding occurs between the arachnoid membrane and the pia mater. A 
serious complication of SAH is vasospasm, in which the blood vessels constrict 
consequently restricting blood flow, and causing ischemic brain injury (delayed 
ischemia) [15].  
2.1.2. Risk factors of stroke 
Risk factors of stroke comprise of inherent biological traits, physiological 
characteristics, behaviour, social characteristics and environmental features [16,17]. 
Inherent biological traits consist of characteristics that cannot be altered such as age and 
sex. Physiological factors predict future occurrence of stroke such as high blood 
pressure, serum cholesterol levels, blood glucose or plasma fibrinogen concentrations. 
At population level, behaviour, such as smoking and alcohol consumption are the most 
important modifiable risk factors. Social characteristics, encompassing social class and 
ethnical groups, and environmental features such as temperature are also important risk 
factors. 
DOI:10.14753/SE.2017.2102
10 
 
2.1.3. Incidence and mortality of cerebrovascular diseases 
According to WHO´s global mortality report in 2015, 17 million deaths are attributed to 
cerebrovascular diseases annually, of which 6.24 million deaths are stroke associated. 
Approximately 795000 individuals experience stroke each year in the United States, 
610000 of these are first attacks, and 185000 are recurrent attacks [2]. Of all strokes, 
87 % are due to ischemic origin, 10 % is due to intracerebral hemorrhage, whereas 3 % 
is SAH stroke. Approximately 40000-50000 acute stroke events occur in Hungary 
annually, from which circa 40 % is fatal within 30 days [18,19].  
2.2. Cerebral circulation 
The cerebral circulation differs in many aspects from the systemic circulation. Brain is 
enclosed in the skull that does not allow the expansion of either tissue or extracellular 
fluid; therefore a tight regulation of cerebral blood flow is required. A unique property 
of the cerebral circulation is that large arteries account for a greater proportion of 
vascular resistance in the brain than in other vascular beds. This unusual function of 
large cerebral arteries facilitates constant blood flow to neuronal tissue and protects the 
cerebral microcirculation during fluctuations in arterial pressure [20].  
2.2.1. Anatomy  
The brain is one of the most highly perfused organs in the body receiving approximately 
750 milliliters of blood per minute, 15 % of the cardiac output [21]. Blood is supplied 
by the right and left internal carotid and the right and left vertebral arteries. The 
internal carotid arteries principally supply the cerebrum, whereas the two vertebral 
arteries join distally to form the basilar artery [20]. Branches of the vertebral and 
basilar arteries supply blood for the cerebellum and brain stem. Proximally, the basilar 
artery joins the two internal carotid arteries and other communicating arteries to form a 
complete anastomotic ring at the base of the brain known as the circle of Willis, from 
which stems three pairs of main arteries, the anterior, middle, and posterior cerebral 
arteries (Figure 1), which divide into progressively smaller arteries and arterioles that 
run along the surface within the pia–arachnoid. These pial vessels give rise to smaller 
arteries that eventually penetrate into the brain tissue through the Virchow–Robin space 
that is a continuation of the subarachnoid space. The penetrating arteries become 
parenchymal arterioles once they penetrate into the brain tissue and supply blood to the 
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corresponding regions of the cerebral cortex. The cerebral venous system comprises of 
superficial cortical veins that are located in the pia matter on the surface of the cortex 
and drain the cerebral cortex and subcortical white matter. The deep or central veins 
consist of subependymal veins, internal cerebral veins, basal vein, and the great vein of 
Galen. Venous outflow is directed via a confluence of sinuses toward the sigmoid 
sinuses and jugular veins. The cerebellum is drained primarily by two sets of veins, the 
inferior cerebellar veins and the occipital sinuses. The brain stem is drained by the veins 
terminating in the inferior and transverse petrosal sinuses [20]. 
 
Figure 1. Circle of Willis. Modified after 20th U.S. edition of Gray’s Anatomy of the 
Human Body [22]. 
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2.2.2. Regulation of cerebrovascular tone 
Normal neuronal function requires constant supply of glucose and oxygen; therefore, 
the control of the cerebral blood flow (CBF) is tightly regulated. While any changes in 
blood flow is directly proportional to the fourth power of radius (Poiseuille´s law), even 
small changes in lumen diameter have significant effects on cerebral blood flow. Hence, 
this mechanism is the most effective to control vascular resistance and regulate regional 
as well as global cerebral blood flow [21]. Essentially, feed-forward mechanisms are 
responsible in the control of the cerebrovascular tone; the activation of these regulatory 
pathways precedes the imbalance between oxygen supply and demand, which in turn 
prevents the loss of function of the neurons. Alterations in the cardiorespiratory system 
leading to decreased oxygen and glucose transport directly influence the 
cerebrovascular tone, eliciting compensatory changes in the vascular diameter. The 
regulatory mechanisms involved in the control of CBF consist mainly of myogenic, 
metabolic, endothelial and neuronal components (Figure 2) [23]. 
Figure 2. Mechanisms involved in the regulation of the cerebrovascular tone. Modified 
after Benyó et al; 2016 [23]. 
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2.2.2.1. Autoregulation of cerebral blood flow 
Autoregulation is the ability of a given vascular bed to maintain constant blood flow, 
despite changes in the mean arterial pressure [24]. This feature is well-developed in the 
brain to supply the necessary nutrients to neurons, since cerebral blood flow is constant 
when mean arterial pressure changes between approximately 60-160 mmHg, but outside 
of this range, autoregulation is lost and CBF becomes linearly dependent on mean 
arterial pressure. Although the exact mechanism underlying cerebral autoregulation 
eludes us, the endothelium, perivascular innervation and myogenic responses seem to be 
involved. Autoregulation is highly adaptable, its limits shift to higher values in 
hypertensive patients [25], but can easily be impaired by various factors such as brain 
damage due to direct trauma, anoxia, prolonged anesthesia, or hypercapnia [26]. 
2.2.2.2. Myogenic response 
Myogenic response is an intrinsic property of smooth muscle to respond to changes to 
mechanical load and intravascular pressure [27]. Arteries contract in response to 
increased intravascular pressure and dilate in response to decreased pressure, thereby 
limiting changes in blood flow [28,29]. This phenomenon is termed autoregulation. 
Although myogenic activity is an innate smooth muscle property, it is modulated by the 
release of vascoactive factors from both endothelium and perivascular nerves and affect 
vascular resistance. Under physiological, resting conditions resistance arteries and 
arterioles display a basal tone, called myogenic tone, which is a state of partial 
constriction at a constant pressure [30]. Alteration in tone in response to pressure 
change is termed myogenic reactivity [30]. At excessively high arterial pressure 
exceeding the autoregulatory pressure range, the vascular tone is lost, and the diameter 
increases markedly, known as forced dilation [30].  
2.2.2.2.1. Myogenic tone 
Intracellular calcium increase initiates the myogenic response via opening of voltage-
dependent calcium channels (Cav) due to increased pressure and consequent 
depolarization of smooth muscle cell membrane [31-33]. The rise in intracellular 
calcium either from intracellular stores (sarcoplasmic reticulum) or extracellular 
sources, leads to the activation of calmodulin and consequent phosphorylation of 
myosin light chain kinase (MLCK) (Figure 3), subsequent phosphorylation of myosin 
DOI:10.14753/SE.2017.2102
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light chain (MLC) and vasoconstriction. Removal of extracellular calcium abolishes the 
myogenic response [32,33]. Although the initiation of the myogenic response is clearly 
calcium dependent, the primary mechanosensor that transduces the change in pressure 
into depolarization and vasoconstriction is not clear. Stretch-activated cation channels, 
such as transient receptor potential (TRP) channel 6 and melastatin TRP 4, have been 
shown to contribute to vascular smooth muscle depolarization [34,35]. Besides TRP 
channels, chloride channels have been proposed to participate in pressure-induced 
smooth muscle depolarization resulting in increased entry of calcium through voltage-
dependent calcium channels and consequently vasoconstriction [36]. 
Mechanotransduction initiated by ion channel activity leads to stimulation of actin 
polymerization, reduction in G-actin content in vascular smooth muscle, formation of 
contractile stress fibers and increase in force production [37]. Both integrins and TRP 
channels are linked to the actin cytoskeleton, thereby providing a possible mechanism to 
transduce pressure into a depolarization and contractile response [38]. 
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Figure 3. Intracellular signaling underlying vascular smooth muscle cell contraction. 
Modified after Kauffenstein et al; 2012 [38]. (CAM, Calmodulin; CPI-17, Protein 
kinase C potentiated Protein phosphatase-1 Inhibitor of 17 kDa; DAG, Diacylglycerol; 
GPCR, G-protein coupled receptor; PKC, Protein kinase C; PLCβ, Phospholipase Cβ; 
MLC, Myosin light-chain; MLCK, Myosin light-chain kinase; MLCP, Myosin 
light-chain phosphatase)  
2.2.2.2.2. Myogenic reactivity 
Myogenic reactivity on the other hand is modulated by vasoactive stimuli, rather than 
intravascular pressure. Smooth muscle contraction and relaxation is primarily dependent 
on the phosphorylation state of MLC and is under dual control by MLCK and myosin 
phosphatase (MLCP) [39-41]. The classical pathway leading to MLCK activation is 
mediated through Gq/11 subtype of G-protein coupled receptors (GPCR). Binding of the 
ligand leads to phospholipase Cβ (PLCβ) activation and results in inositol-1,4,5-
trisphosphate (IP3) formation. IP3 binds to its corresponding receptor on the 
sarcoplasmic reticulum leading to an increase of intracellular free Ca
2+
 concentration. 
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The complex of Ca
2+
 and calmodulin activates MLCK, which in turn phosphorylates 
and activates MLC. While the Gq/11 mediated pathway requires Ca
2+
, a Ca
2+
 independent 
regulation also exists, termed calcium sensitization. The pathway is initiated by G12/13 
stimulation and subsequent activation of Rho-specific guanine exchange factors 
(RhoGEF), including PDZ-RhoGEF, p115RhoGEF and LARG [42,43], leading to 
RhoA and Rho-kinase activation and phosphorylation and inactivation of myosin 
phosphatase [44].  
2.2.2.3. Endothelial regulation of tone 
Endothelium is a specialized, single cell layer, covering the luminal side of the vessel. It 
is involved in numerous physiological processes, including regulation of inflammatory 
and immune responses, thrombosis, adhesion, angiogenesis, and permeability [20]. 
Also, it creates a barrier between the cerebral extracellular fluid and circulating blood 
that is permeable to water, gases, and lipid-soluble molecules, but transports selectively 
glucose and amino acids which are required for neuronal function. This uniquely 
specialized endothelium forming the blood-brain barrier is phenotypically different 
from the endothelium localized in the periphery; they form apical tight junction 
complexes that are highly similar to epithelium rather than endothelium [45,46]. Three 
integral proteins form tight junctions (claudin, occludin and junction adhesion 
molecules). Claudins are small phosphoproteins, and they comprise the most abundantly 
expressed component of tight junctions; claudins on adjacent endothelial cells bind 
homotypically to form the tight junction, thereby regulating paracellular permeability 
[47]. Occludins form tight junctions with claudins on neighboring cells; they differ from 
claudins in that while claudins require accessory proteins (zona occludens proteins and 
cingulin) to link it to the actin cytoskeleton [48], occludins directly bind to actin 
[49,50]. Junction adhesion molecules also require zona occludens proteins to couple to 
actin, although its exact mechanism is not fully characterized [51]. The cerebral 
endothelium also lacks fenestrations and displays low rate of pinocytosis; both features 
are unique to cerebral endothelium and important in the formation of a highly restricted 
and carefully controlled barrier to plasma constituents [20]. 
Furthermore, the endothelium produces several vasoactive mediators, most importantly 
nitric oxide (NO), prostacyclin (PGI2), and endothelium-derived hyperpolarizing factor 
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(EDHF) that have a significant influence on vascular tone and consequently on cerebral 
blood flow. 
2.2.2.3.1. Nitric oxide 
Nitric oxide, historically termed endothelium-derived relaxant factor [52], is a short 
half-lived gaseous signaling molecule, produced from L-arginine, oxygen and NADPH 
by nitric oxide synthase (NOS). The endothelium synthesizes NO that diffuses freely to 
smooth muscle and interacts with soluble guanylate-cycles to generate cyclic GMP 
(3’,5’-guanosine monophosphate) (cGMP) from guanosine triphosphate (GTP). The 
soluble cGMP stimulates protein kinase G (PKG) activity, a serine/threonine kinase that 
promotes the opening of calcium-dependent potassium channels, resulting in 
hyperpolarization, inhibits PLC activity, consequently causing smooth muscle 
relaxation and activates KATP channels, promoting channel opening [53-55]. 
Furthermore, PKG directly phosphorylates MLCP in a stimulatory fashion, resulting in 
the dephosphorylation of MLC; additionally, PKG also phosphorylates RhoA, 
phospholamban and IRAG on inhibitory phosphosites, hence inhibits the activation of 
ROCK, increases Ca
2+
-sequestration and decreases Ca
2+
-release [56]. Three different 
NOS isoforms are present in the brain; neuronal (nNOS) and endothelial (eNOS) are 
constitutively expressed in neurons and cerebral endothelium, respectively, and 
inducible (iNOS) expression is induced under certain pathological conditions. eNOS 
activity can be stimulated by increase in intracellular calcium [5], the result of either 
binding of a vasoactive ligand (such as acetylcholine, bradykinin) or shear stress 
induced phosphorylation cascade [57]. During NO production, free radicals are 
produced, such as O2
-
 and hydrogen peroxide, when lower than optimal concentration of 
the essential co-factor tetrahydrobiopterin (BH4) is available. This uncoupling 
phenomenon results in lower NO bioavailability, generation of reactive oxygen species 
and endothelial dysfunction [5]. 
2.2.2.3.2. Prostacyclin 
Increase in intracellular calcium induces arachidonic acid metabolism via phospholipase 
A2 to produce arachidonic acid lipid precursors that are substrates for cyclooxygenase 
(COX), lipoxygenases, and cytochrome P450 monooxygenases [for further details 
please refer to 2.3.1]. Prostacyclin is produced from prostaglandin H2 and performs its 
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function through paracrine signaling on prostacyclin receptor activating adenylate 
cyclase, leading to increased cyclic AMP (cAMP) production and protein kinase A 
(PKA) stimulation in smooth muscle [58]. In turn PKA phosphorylates MLCK, 
reducing its activity that consequently leads to smooth muscle relaxation and 
vasodilation [58]. 
2.2.2.3.3. Endothelium-derived hyperpolarizing factor 
Endothelium-derived hyperpolarizing factor includes vasoactive metabolites that are 
responsible for the residual vasodilator mechanism after NOS and COX inhibition. 
Although the chemical nature of EDHF remains elusive, it has been shown that the 
effect of EDHF on small penetrating parenchymal arteries depends on the activity of 
small and intermediate calcium-activated potassium (SKCa and IKCa respectively) 
channels [59]. Recent evidence suggests that K
+
 released from endothelial cells into the 
myoendothelial junction activates the Na
+
-K
+
-ATPase and KIR (inwardly rectifying K 
channels), and is responsible for the hyperpolarization of smooth muscle (or 
repolarization in the presence of vasoconstrictor) [60,61]. In the brain, it has been 
proposed that in addition to K
+
, epoxyeicosatrienoic acids, hydrogen peroxide, 
anandamide, C-type natriuretic peptide and interestingly, ATP may convey EDHF 
related responses [62]. 
2.2.2.4. Perivascular nerves and neural-astrocyte regulation 
Extracerebral vessels, located at the base and surface of the brain, are innervated by 
perivascular nerves originating from the superior cervical ganglion, responsible for the 
sympathetic innervation, the sphenopalatine and otic ganglia, mainly supplying 
parasympathetic nerves, as well as the trigeminal ganglion [63]. This extrinsic 
innervation disappears when perforating arteries enter the brain. These parenchymal 
arterioles have unique properties compared to the microvasculature found in other 
organs; the endothelial cells are wrapped around by specialized contractile cells, termed 
pericytes or Rouget cells [64], that are embedded in the basement membrane, separating 
it from the endothelial cells, and project a sheath around endothelial cells, in which they 
communicate with the endothelium through either synapse-like direct contact or with 
paracrine signaling [65]. Pericytes have important homeostatic and hemostatic functions 
in the brain by stabilizing the maturation of endothelial cells, as well as regulating 
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capillary blood flow, phagocytosis and clearance of cellular debris, and the permeability 
of the blood-brain barrier [64,66]. The basal lamina of the cerebral microvasculature is 
in close connection with astrocytes and neurons that regulate the surrounding 
microcirculation, hence it is termed intrinsic innervation. Intrinsic efferents originate 
from subcortical neurons, such as the basal forebrain, the raphe nucleus, locus coreuleus 
or local cortical interneurons [67,68]; however this type of innervation targets mainly 
astrocytes rather than parenchymal arterioles [67]. Common feature of both extrinsic- 
and intrinsic innervation is that nerve endings do not form classical synaptic junctions, 
but contain varicosities, thereby modulating directly the vascular tone upon stimulation 
[63]. The main role of the sympathetic innervation, besides the direct effect of 
vasocontraction, is to shift the upper limit of autoregulation toward higher pressure, thus 
protecting the brain against high blood pressure. The parasympathetic system causes 
vasodilation and it appears to be involved in pathological situations, such as ischemia 
and migraine [69]. Intrinsic innervation is based on the neuronal-astrocytic-vascular 
tripartite unit, also called neurovascular unit [63]. The innervating fibers sent by the 
neurons to microvessels and astrocytes contain acetylcholine and nNOS that are 
responsible for vasodilation and local increase in CBF. Astrocytes are targeted by both 
noradrenergic and cholinergic neurons, and are responsible for modulating the vascular 
tone in accordance with neuronal demand [63].  
2.2.2.5. Effect of arterial gas tensions 
Due to the high metabolic demand of the brain, it is not surprising that reduction in 
arterial oxygen tension (PaO2) or increase in arterial carbon dioxide tension (PaCO2) are 
potent dilators in the cerebral circulation. Hypoxia (<50 mmHg PaO2) increases CBF, as 
well as oxygen extraction from blood. Decrease in ATP levels due to hypoxia activates 
potassium channels (KATP) causing hyperpolarization in smooth muscle cells and a 
consequent vasodilation [70,71]. Furthermore, adenosine acting on its A2-type receptor 
increases adenylyl-cyclase activity and consequent increase in cAMP levels, leading to 
the activation of PKA [72]. Although direct evidence is lacking, it has been proposed 
that PKA directly phosphorylates KATP channels, contributing to the opening of the 
channel [72]. On the other hand, even small changes in PaCO2 modulate cerebral 
perfusion. Hypercapnia relaxes cerebrovascular smooth muscle, an increase in PaCO2 
over 50 mmHg increases CBF by more than 50%, whereas hypocapnia produces 
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vasoconstriction [73]. Carbon dioxide induces changes in the extracellular hydrogen ion 
concentration that directly act as vasoactive mediator on vascular smooth muscle and 
may also modulate the effects of other vasoactive agents, such as noradrenalin [74]. 
Vasodilation during hypercapnia is also dependent on nitric oxide formation [75,76], 
partially due to acidosis that increases the activity of NOS [75] and, as shown more 
recently, due to direct influence of PaCO2 on NO production [77].  
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2.3. Lipid mediators 
Lipid mediators are bioactive lipids that are synthesized and released to external stimuli, 
and act on their corresponding receptors as local hormones or autacoids. Structurally 
they are divided into three categories. Class 1 includes arachidonic acid derived 
metabolites, called eicosanoids, such as prostaglandins (PG) and leukotrienes (LT). 
Class 2 includes lysophospholipids, including platelet-activating factor (PAF), 
lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P). Class 3 consists of 
newly identified anti-inflammatory lipids derived from ω-3 polyunsaturated fatty acids 
(PUFA) [78]. 
2.3.1. The arachidonic acid cascade 
Arachidonic acid (AA) is a carboxylic acid with a 20-carbon chain that contains four 
cis-double bonds, where the first double bond is situated at the sixth carbon atom from 
the omega end. Arachidonic acid is released by enzymatic cleavage from membrane 
phospholipids, mainly phosphatidylethanolamine, phosphatidylcholine, and 
phosphatidylinositides by phospholipase A2 (PLA2) or generated from diacylglycerol 
(DAG) by diacylglycerol lipase.  
2.3.1.1. Eicosanoids 
Arachidonic acid can be further metabolized via cyclooxygenase (COX) forming 
prostanoids, lipoxygenase (LOX) resulting in leukotriene formation, or via cytochrome 
P-450 producing hydroxyeicosatetraenoic acids (HETE) and epoxides. Oxygenated 
conversion of AA via either constitutive COX-1 or inducible COX-2 produces PGG2 
and then PGH2. PGH2 is further metabolized to one of the five major prostanoids that 
have been identified, namely PGE2, PGD2, PGF2α, PGI2 and thromboxane A2 (TXA2). 
They play various biological roles based on their receptor coupled to G protein subunits; 
PGE2 has four receptor subtypes (EP1-EP4), PGD2 has two (DP1-DP2), and specific 
receptors bind PGF2α, PGI2 or TXA2 (FP, IP and TP, respectively) [79]. Gs coupled 
receptors are IP, DP1, EP2 and EP4 and act as relaxant receptors, on the other hand EP1, 
FP and TP signal through Gq subunit leading to increase in intracellular Ca
2+
 
concentration and contraction. DP2 and EP3 receptors bind Gi/o subunit, decreasing 
adenylate cyclase activity (Table 1) [80]. Prostaglandins were first isolated from the 
prostate and seminal vesicles, hence the name [81]. Table 2 shows the various 
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physiological effects of the different metabolites; PGD2 is released from mast cells and 
alveolar macrophages, and induces bronchoconstriction and inhibition of platelet-
activating factor (PAF). PGF2α is a potent vasoconstrictor also involved in uterine and 
bronchial smooth muscle contraction. PGE2 is responsible for maintaining the 
physiological function of gastric mucosa by regulating the gastric mucosal blood flow, 
bicarbonate and mucus production. PGI2 shows anti-aggregatory and vasodilating 
properties, as well as counteracts thromboxane effects. Thromboxane is mainly 
produced in the vascular smooth muscle, endothelium and platelets, and as the name 
indicates, TXA2 is a very potent aggregating agent; in addition it induces 
vasoconstriction and bronchoconstriction. TXA2 is chemically unstable and rapidly 
metabolized to thromboxane B2 that is biologically inactive; considering the short 
half-life of TXA2, its stable synthetic analog, U-46619, is used in research. 
Lipoxygenases convert AA to hydroperoxyeicosatetraenoic acids (HPETE) and HETE. 
5-HETE is the precursor substance for leukotriene LTA4 which can be further 
metabolized to LTB4, cysteinyl-LT (LTC4, LTD4, and LTE4) and lipoxins (LX). The 
effect of LTB4 is mediated through BLT1 and BLT2 receptors acting on Gi/o and Gq, 
while cyteinyl-LT acts on CysLT1 and CysLT2 receptors via Gq and Gi/o mechanisms 
[80]. Leukotrienes are responsible for inflammatory and hypersensitivity disorders, such 
as asthma; LTs are released from leukocytes, monocytes and macrophages, cells 
involved in inflammation. The release of LTs results in bronchoconstriction, 
vasoconstriction and an increase in vascular permeability. Lipoxins are mainly involved 
in the resolution of inflammation; the receptor activity inhibits chemotaxis, 
transmigration, superoxide anion generation and NF-κB activation. 
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Table 1. Physiological ligands and coupling of eicosanoid receptors 
ENDOGENOUS LIGAND RECEPTOR 
COUPLING TO G PROTEIN 
SUBCLASS 
LEUKOTRIENE B4 (LTB4) BLT Gq/11, Gi/o 
LTC4, LTD4 CysLT1, CysLT2 Gq/11, Gi/o 
PROSTACYCLIN (PGI2) IP Gs 
PROSTAGLANDIN D2 (PGD2) 
DP1 Gs 
DP2 Gi/o 
PROSTAGLANDIN F2α (PGF2α) FP Gq/11 
PROSTAGLANDIN E2 (PGE2) 
EP1 Gq/11 
EP2, EP4 Gs 
EP3 Gs, Gq/11, Gi/o 
THROMBOXANE A2 (TXA2) TP Gq/11, G12/13 
Table 2. Physiological effects of major eicosanoids 
TISSUE BIOLOGICAL EFFECTS EICOSANOIDS 
VESSELS 
Vasoconstriction PGF2, TXA2, LTC4, LTD4 
Vasodilatation PGI2, PGE2, PGD2 
PLATELETS 
Anti-aggregation PGE1, PGI2 
Pro-aggregation TXA2 
BRONCHI 
Bronchoconstriction 
PGD2, PGF2α, TXA2, 
LTC4, LTD4 
Bronchodilation PGE2, PGI2 
INTESTINES 
Nausea, diarrhoea PGE1, PGF2α 
Motility PGE1, PGF2α 
STOMACH 
Inhibition of gastric acid secretion PGE2, PGI2 
Motility PGE2, PGF2α 
UTERUS Contraction, parturition PGE2, PGF2, TXA2 
KIDNEY Filtration and renal blood flow PGH2, PGE1, PGI2 
HYPOTHALAMIC AND 
PITUITARY AXIS 
Increase in hypothalamic and pituitary 
hormone secretion 
PGE1, PGE2 
2.3.1.2. Endocannabinoids 
Endocannabinoids are endogenous bioactive ligands for specific G-protein coupled 
receptors; arachidonoyl ethanolamide (anandamide) [82] acting mainly on cannabinoid 
receptor 1 (CB1) and 2-arachidonoyl glycerol (2-AG) [83] on CB1 and cannabinoid 
receptor 2 (CB2). Although the major neurotransmitter systems have been well 
characterized, the endocannabinoid system remained unknown until the early 1990s 
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[84]. Originally the effect of Δ9-tetrahydrocannabinol (THC), produced by Cannabis 
sativa (marijuana), was believed to act nonspecifically on neural membranes. Emerging 
pharmacological data indicated specific effect of cannabinoids and in 1990. First CB1 
and three years later, CB2 receptor were cloned [85]. Anandamide and 2-AG are 
synthesized by neurons on demand and undergo depolarization-induced release. Once 
they are released they are swiftly cleared from the synaptic cleft by reuptake and 
degraded by fatty acid amide hydrolase (FAAH ) that cleaves anandamide into AA and 
ethanolamine or by monoacylglycerol lipase cleaving 2-AG into AA and glycerol [86]. 
CB1 receptors are expressed widely in the central nervous system (CNS), as well as in 
specific peripheral tissues, including the pituitary gland, immune cells, reproductive 
tissues, gastrointestinal tissue, sympathetic ganglia of the heart, lung and urinary 
bladder [87]. In contrast, CB2 are expressed mainly in immune cells. Both receptors 
signal through Gi/o subunits, negatively affecting adenylate cyclase activity and 
positively impacting mitogen-activated protein kinase. Under certain conditions, CB1 
can couple to Gs, but its physiological importance is yet to be resolved [87]. To study 
the physiological role of CB1 and CB2 receptors, selective ligands have been 
synthetized. SR141716A (rimonabant) is described as a CB1 specific, selective 
antagonist, while the compound may produce inverse cannabimimetic effect in certain 
tissues by reducing the constitutive activity of the receptor [87]. The most commonly 
used selective antagonist (or inverse agonist) against CB2 are SR144528 and AM630. 
Two structural analogs of SR141716A are marketed, namely AM-251 and AM281, 
which have been found to be less potent than SR141716A, but have higher affinity to 
CB1 receptors [87]. Several agonists have been described, of these, HU-210 and 
WIN55212 are the most widely used in pharmacological studies; both agonists bind 
CB1 and CB2 equally well. Another possibility to stimulate the endocannabinoid 
system is to inhibit its rapid clearance by reuptake inhibitor, namely AM-404. Although 
the exact mechanism of the inhibition is not yet fully elucidated, it has been shown that 
AM-404 prevents the reuptake of anandamide as well as blocks the metabolism by 
inhibiting FAAH-mediated hydrolysis; besides AM-404 also blocks COX activity [88]. 
The role of the endocannabinoid system appears to be the regulation of spontaneous or 
evoked release of chemical transmitters. Hence neurotransmitter release can be inhibited 
through presynaptic CB1 receptors, as well as the release of cytokines from immune 
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cells can be altered via CB1/CB2 receptors. Besides the canonical cannabinoid 
receptors, other non-cannabinoid receptors and ion channels have been proposed to be 
activated or inhibited by endocannabinoid ligands (Table 3). One of the G protein-
coupled receptors, GPR55, demonstrated activation and Ca
2+
 mobilization when 
stimulated with anandamide, 2-AG or noladin ether in heterologous overexpression 
system [89,90]; however the exact physiological relevance of GPR55 is not yet 
established [84]. Numerous ligand-gated ion channels respond to endocannabinoids; 
anandamide exhibit allosteric inhibition on serotonin (5-hydroxytryptamine) receptor 3 
[91,92], although contradictory evidence has also been published [93]. Nicotinic 
acetylcholine receptor activation by either nicotine or acetylcholine is antagonized in a 
non-competitive manner by anandamide and 2-AG, albeit the exact underlying 
mechanism is still largely unknown [94]. Glycine receptor activation in heterologous 
expression systems is further enhanced in the presence of anandamide [95,96]; however, 
contradictory evidence has emerged, where isolated hippocampal neurons exhibited 
inhibition of glycine receptors in the presence of anandamide or 2-AG, and this effect 
was independent of CB1 or TRPV1 receptors [97]. Additionally, TRPV1 receptors have 
been found to increase Ca
2+
 influx when stimulated with anandamide [98]. 
Table 3. Endogenous endocannabinoid and non-cannabinoid receptors and their 
putative ligands 
TARGET CLASS TARGET NAME ENDOGENOUS COMPOUND 
GPCR 
CB1 
anandamide, 2-AG, noladin ether, virodhamine, 
oleamide 
CB2 anandamide, 2-AG 
GPR55 anandamide, 2-AG, noladin ether, virodhamine 
LIGAND-GATED ION 
CHANNEL 
5-HT3 anandamide 
Nicotinic acetylcholine anandamide, 2-AG 
Glycine anandmaide, 2-AG 
TRP CHANNEL TRPV1 anandamide, 2-AG 
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Endocannabinoids exert their pharmacological actions in the nervous system by 
modulating neurotransmitter release [99]. Their inhibitory effects on presynaptic Ca
2+
 
channels counteract depolarization and the consequent release of neurotransmitters, as 
well as the facilitatory effect on inwardly rectifying K
+
 channels prevents neuronal 
depolarization and action potential generation. However, in certain regions, 
endocannabinoids may potentiate neurotransmitter release [99] (Table 4). It has been 
shown previously that CB1 receptor inhibition enhances acetylcholine and glutamate 
release in the hippocampus [100,101], which consequently improves working memory 
in rodents, implicating that endocannabinoids tonically suppress glutamate and 
acetylcholine release. The analgesic effect of endocannabinoids has been linked to the 
inhibition of glutamate-mediated neurotransmission in the dorsal root ganglia and 
periaqueductal grey matter [83]. The neurotransmitter release from the peripheral 
autonomic nervous system is also modulated by endocannabinoids; activation of 
prejunctional CB1 receptors induces smooth muscle relaxation, hypotension and 
bradycardia [102]. The importance of the neuromodulatory action of endocannabinoids 
in the cardiovascular system depends on whether the animal is conscious or under 
anaesthesia [103]. Application of anandamide in anaesthetised animals elicits a triphasic 
response; a rapid, transient bradycardia, followed by a transient increase in blood 
pressure and then a prolonged hypotensive phase [104]. The initial phase of bradycardia 
is mediated by TRPV1 receptors [105]; the rapid pressor response during the second 
phase is associated with TRPV1, NMDA and β2–adrenoceptor activity [104]. The 
prolonged hypotensive effect of anandamide is thought to be CB1 receptor dependent 
[106]. Interestingly, 2-AG induces strong hypotension accompanied with tachycardia; 
both effects are independent of CB1 receptors, and most likely involve other 
arachidonic acid metabolites [107]. Conversely, in conscious animals anandamide 
elicits lasting bradycardia and transient hypotension, followed by lasting increase in 
blood pressure accompanied with vasoconstriction in renal and mesenteric vascular beds 
[108,109]. The complex effect of endocannabinoids in conscious state is attributed to 
the increased level of circulating adrenaline; TRPV1 receptors have limited effect on the 
hemodynamic regulation in conscious state [109]. 
In the cerebral vasculature, endocannabinoids act as vasodilators via vasoactive 
prostanoid release [110]. Furthermore, activation of CB1 receptors in cerebral vascular 
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smooth muscle cells inhibit L-type Ca
2+
 channels, thereby influencing vasorelaxation 
[111]; endocannabinoids acting on CB1 receptors expressed in brain endothelial cells 
counteract the effect of endothelin-1, thus partially reduce cerebral vasoconstriction 
[112]. Given the observed effects of endocannabinoids on the cerebral vasculature, they 
are generally considered as neuroprotective agents during traumatic brain injury and 
stroke events [84]. Indeed, following traumatic injury to the brain, endocannabinoid 
release is enhanced tenfold [113], and the recovery was further enhanced upon 
administration of 2-AG; an effect that was dependent on the presence of CB1 receptors. 
Similarly, after acute stroke events, the circulating plasma levels of endocannabinoids 
were increased [114]; and they have been shown to protect against 
ischaemia/reperfusion, and significantly reduce infarct size [115]. 
Endocannabinoids are also involved in the respiratory regulation, since both the 
systemic administration of phytocannabinoids [116-119] and endocannabinoids [120-
122] demonstrate respiratory depression, which involves CB1 and TRPV1 receptors 
[122]. Administration of the synthetic cannabinomimetic, WIN55212-2 or CP55940 
induced severe cardiovascular depression; however, the observed effects were markedly 
increased in rats that were spontaneously breathing in comparison to the artificially 
ventilated group, suggesting that the cardiovascular depression has been further 
enhanced by the accompanying reduction in respiration and was abrogated by 
pretreatment with a CB1 receptor antagonist, SR141716A [119,122,123]. The release of 
endocannabinoids influences the respiratory regulation mainly centrally, since 
intracisternal injection of WIN55212-2 reduced breath rate and increased the tidal 
volume in rats in a CB1-dependent manner [120,124]. Additionally, CB1 receptor 
inhibition reduced the observed reduction of phrenic nerve activity following 
endocannabinoid injection to the brain stem, indicating the presence of CB1 receptors in 
the respiratory centers in the medulla and the pivotal role of endocannabinoids in the 
respiratory regulation [120]. 
Contradictory with these findings are several studies showing that administration of 
Δ9-THC has no effect on the respiratory parameters in humans [125] as well as in 
primates receiving either Δ9-THC or WIN55212-2, where both cannabinomimetics 
failed to influence the respiratory rate, although reduced the tidal volume [126]. 
 
DOI:10.14753/SE.2017.2102
28 
 
Table 4. Neuromodulatory actions of endocannabinoids in the nervous system. 
Modified after DiMarzo et al.; 1998 [99]  
REGION NEUROTRANSMITTER 
MODULATORY 
ACTION 
ECS INVOLVED 
POTENTIAL 
EFFECT 
HIPPOCAMPUS 
Glutamate 
Inhibition of 
release 
anadamide, 
2-AG 
Inhibition of 
LTP 
Acetylcholine 
Inhibition of 
release 
anadamide, 
2-AG 
Inhibition of 
learning and 
memory 
CEREBELLUM Glutamate 
Inhibition of Ca
2+
 
channel 
anadamide 
Inhibition of 
motor 
coordination 
CORTEX Glutamate 
Inhibition of Ca
2+
 
channel 
anadamide, 
2-AG 
Inhibition of 
memory and 
motor function 
SPINAL CORD Glutamate 
Inhibition of 
release 
2-AG Antinociception 
BASAL GANGLIA 
AND SUBSTANTIA 
NIGRA 
GABA 
Inhibition of 
re-uptake 
anandamide 
Inhibition of 
locomotor 
activity 
Dopamine 
Inhibition of 
synthesis/release 
anandamide 
Inhibition of 
locomotor 
activity 
Dopamine Potentiation anandamide 
Induction of 
contralateral 
turning 
HYPOTHALAMUS Dopamine Potentiation 
Not yet 
identified  
Inhibition of 
prolactin release 
PARA-
SYMPATHETIC 
SYSTEM 
Acetylcholine 
Inhibition of 
release 
Not yet 
identified 
Inhibition of 
smooth muscle 
contraction 
SYMPATHETIC 
NERVOUS 
SYSTEM 
Noradrenaline 
Inhibition of 
release 
anandamide  
Hypotension, 
bradycardia 
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2.3.1.3. Lysophospholipids 
Lysophospholipids are small bioactive lipid molecules that consist of either a sphingoid 
base or a glycerol backbone and a polar head group. The first recognized 
lysophospholipid mediator was PAF, since then S1P and LPA have also been 
characterized. They behave as auto- or paracrine regulators of angiogenesis, lymphocyte 
trafficking, development of the nervous system, cancer growth and metastasis, 
inflammation and arteriosclerosis. PAF is produced from 1-O-alkyl-
lysophosphatidylcholine (LPC) by PLA2 then further acetylated by acyltransferase. It is 
a potent mediator of leukocyte functions, platelet aggregation and degranulation, as well 
as anaphylaxis and inflammation. LPA is produced by autotaxin, and acts via LPA 
receptors (LPA1-6) to regulate brain development, embryo implantation and hair 
growth, and is also associated with pathological conditions, such as neuropathic pain 
and pulmonary fibrosis [78,127]. S1P has sphingosine backbone instead of glycerol, and 
acts via S1P receptors (S1P1-5). It regulates numerous biological processes, such as 
development of vascular integrity, where S1P stimulates proliferation, survival and 
migration of endothelial cells and induces formation of adherens junction assembly, 
thereby decreasing vascular permeability and differentiation of endothelial cells into 
capillary-like networks. Also, lack of S1P receptors results in profound deafness, as 
well as anaphylaxis and it has been proposed to be involved in tumor angiogenesis 
(Table 5) [78]. 
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Table 5. Physiological effects of major lysophospholipids 
ENDOGENOUS 
LIGANDS 
RECEPTOR 
MAIN TISSUE 
DISTRIBUTION 
SIGNALING MAIN BIOLOGICAL EFFECT 
S1P 
S1P1 Ubiquitous Gi/o 
Migration ↑, proliferation, 
survival, cell–cell-contacts, 
angiogenesis, lymphocyte 
trafficking 
S1P2 Ubiquitous Gi/o, Gq, G12/13 
Migration ↓, vascular 
development, differentiation of 
vascular smooth muscle cells 
S1P3 Ubiquitous Gi/o, Gq, G12/13 
Heart rate ↓, vascular 
development, NO-dependent 
vasorelaxation 
S1P4 
Lymphoid and 
hematopoietic 
tissue 
Gi/o, G12/13 
Proliferation and cytokine 
secretion in T-cells ↓ 
S1P5 Brain, white matter  Gi/o, G12/13 Proliferation, cell rounding 
LPA 
LPA1 Ubiquitous Gi/o, Gq, G12/13 
Proliferation, survival, neurite 
retraction, brain development 
LPA2 Ubiquitous Gi/o, Gq, G12/13 Proliferation, survival 
LPA3 Ubiquitous Gi/o, Gq 
Implantation and embryo 
spacing in mice 
2.3.1.4. ω-3 polyunsaturated fatty acid derivatives 
New class of lipid mediators derived from ω-6 arachidonic acid, such as resolvins, 
protectins, maresins and lipoxins, have been proposed to be crucial mediators of the 
resolution of inflammation [78], although in vivo relevance and identification of their 
specific receptor type require further investigation.  
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3. Statement of Purpose 
3.1. Hypersensitivity to Thromboxane Receptor Mediated Cerebral 
Vasomotion and CBF Oscillations during Acute NO-Deficiency in Rats 
Low frequency oscillations [128] of cerebrovascular tone and cerebral blood flow that 
are independent of the cardiac or respiratory cycles [129] have been observed in 
diseases associated with endothelial dysfunction. The decreased bioavailability of 
endothelium-derived nitric oxide under these pathophysiological conditions has been 
shown to promote vasomotion and oscillation in the cerebral blood flow [12,130]. It has 
also been shown that nitric oxide synthase inhibition provokes vulnerability to 
vasomotion that can be triggered by the administration of UTP or U-46619, the 
chemically stable analogue TXA2, and is mediated by TP-receptors in isolated cerebral 
arteries [131]. In the present study we hypothesized that in the absence of NO, 
hypersensitivity of TP-receptor mediated cerebrovascular signaling contributes to the 
development of vasomotion and CBF oscillations in the cerebral cortex of rats [132].  
3.2. Role of Endocannabinoids and Cannabinoid-1 Receptors in 
Cerebrocortical Blood Flow Regulation 
Endocannabinoids have been implicated in various physiological and 
pathophysiological processes, such as hypertension, ischemia-reperfusion injury, 
chemotherapy-induced myocardial injury, hepatic cirrhosis, cardiomyopathy, 
atherogenesis [133], diabetes [134] and obesity [135]. Regardless of multiple literary 
evidence published concerning the role of endocannabinoids in the regulation of 
cerebral blood flow (CBF), the findings were conflicting. It has been shown that 
Δ9-THC and anandamide increases CBF in dogs [136], humans [137] and cats [111], 
but reduces CBF in rats [138]; although, in another study the authors observed that 
anandamide elicited marked cerebral vasodilatation via CB1 receptor mediated 
mechanism in rats [139]. To address these contradictory findings and clarify the role of 
endocannabinoids in the cerebral circulation as well as to overcome the apparent 
limitation of the published results, namely the utilization of exogenously applied 
agonists, in the present study the endogenous cannabinoid levels have been regulated 
via the administration of an EC-reuptake inhibitor (AM-404). Furthermore, we have 
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tested the effect of a CB1 receptor antagonist/inverse agonist (AM-251) in order to 
characterize the influence of constitutively active CB1 receptors in the cerebrovascular 
and cardiovascular regulation under resting conditions [140]. 
3.3. Cannabinoid-1 Receptor-mediated Respiratory Depression by 
Endocannabinoids  
The endogenous bioactive mediators of Cannabis sativa (marijuana), are anandamide 
(AEA) and 2-arachidonoyl glycerol (2-AG). While anandamide favors cannabinoid 
receptor 1 (CB1), 2-AG acts both on CB1 and cannabinoid receptor 2 (CB2) [98]. Both 
receptors are widely expressed in different tissues, including the respiratory system. 
Although numerous previous studies have observed that either exogenously applied 
phytocannabinoids [116] or synthetic or endogenous cannabinomimetics [119-124] 
elicited marked cardiovascular depression, which were dependent on the respiratory 
state of the animals, the exact mechanism underlying the influence of ECs on the 
respiratory regulation is still largely unknown. Anaesthetized, spontaneously breathing 
rats [119] and cats [116] showed lasting reduction in respiratory rate (RR) upon 
systemic injection of cannabinomimetics. Central application of the synthetic CB1/CB2 
agonist, WIN55212-2, to the cisterna magna induced direct activation of brain stem 
respiratory regulatory centers, reduced RR and increased the tidal volume in rats 
[120,124]. Further investigation proposed CB1 to mediate the aforementioned 
respiratory effects [119], since systemic administration of SR141716A (rimonabant) 
abolished the respiratory depression. In our previous study the pivotal role of 
endogenously released ECs have been implicated in the control of breath regulation in a 
CB1-dependent manner [140], but direct evidence was lacking, because respiratory 
parameters were not measured. Conflicting with the aforementioned findings are several 
studies performed in humans [125,141,142] and conscious monkeys [126] that reported 
no changes in RR and tidal volume upon administration of Δ9-Tetrahydrocannabinol or 
WIN55212-2. To unambiguously clarify the role of the endogenous cannabinoid system 
in respiratory control, in our present study respiratory parameters were recorded using 
pulse oximetry after enhancing EC levels by administration of an EC-reuptake inhibitor 
(AM-404). The experiments have been performed both in wild-type control and CB1-
deficient (CB1-KO) mice in order to analyze the involvement of CB1 receptors [143].  
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4. Experimental Animals, Materials and Methods 
4.1. Animals 
The experiments were performed in (1) adult male Wistar rats (300-400 g) according to 
the guidelines of the Hungarian Law of Animal Protection (243/1988) and all 
procedures were approved by the Semmelweis University Committee on the Ethical Use 
of Experimental Animals (590/99 Rh); and in (2) CB1-KO mice that were generated as 
previously described [144] and kindly provided by Dr. Andreas Zimmer (Institute of 
Molecular Psychiatry, University of Bonn, Germany). 
4.2. Materials 
The CB1 receptor antagonist/inverse agonist AM-251 (1-(2, 4-dichlorophenyl)-5-(4-
iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide) and the 
endocannabinoid reuptake inhibitor AM-404 (N-(4-hydroxyphenyl)-5Z, 8Z, 11Z, 14Z-
eicosatetrenamide) were obtained from Cayman Chemicals (Ann Arbor, MI, USA); 
both chemicals were dissolved in 1 ml of vehicle containing ethanol/emulphor/saline 
(1:1:8; v:v:v). Ketamine (Calypsol) and xylazine (CP-Xylazine) were purchased from 
Richter Gedeon Plc. (Budapest, Hungary) and CP-Pharma GmbH (Burgdorf, Germany), 
respectively. The thromboxane A2 receptor agonist U-46619 (9,11-dideoxy-9α,11α-
methanoepoxy Prostaglandin F2α), the thromboxane A2 inhibitor Ozagrel (sodium;(E)-3-
[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoate), the inhibitor of nitric oxide synthase 
L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride), and the specific 
Rho-kinase inhibitor Y-27632 ((R)-(+)-trans-4-(1-Aminoethyl)-N-(4-Pyridyl) 
cyclohexanecarboxamide dihydrochloride), bradykinin, Uridine-5'-triphosphate (UTP), 
endothelin-1 (ET-1) and Urethane (Carbamic acid ethyl ester) were purchased from 
Sigma (St. Louis, MO, USA) (Table 6). 
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Table 6. Biochemical and physiological actions of the chemicals used. 
CHEMICAL PRODUCT NAME BIOCHEMICAL AND PHYSIOLOGICAL ACTION 
AM-251 CB1 receptor antagonist/inverse agonist 
AM-404 Endocannabinoid reuptake inhibitor 
Ketamine NMDA receptor antagonist, anaestheticum 
Xylazine α2 adrenergic receptor agonist, muscle relaxant 
U-46619 Thromboxane A2 receptor agonist 
Ozagrel Thromboxane A2 synthesis inhibitor 
L-NAME Nitric oxide synthase inhibitor 
UTP P2Y receptor agonist, vasoconstrictor 
Bradykinin Endothelium-dependent vasodilator 
ET-1 Vasoconstrictor 
Y-27632 
Rho-associated coiled coil forming protein serine/threonine kinase 
(ROCK) inhibitor 
Urethane 
Nicotinic acethylcholine receptor, gamma aminobutyric acid and 
glycine receptor agonist, NMDA receptor antagonist, anaestheticum 
4.3. Methods of Measurement 
4.3.1. Anesthesia and Interventions 
Wistar rats were anesthetized with urethane (1.5 g kg
-1
 intraperitoneally), the depth of 
anesthesia was regularly controlled during the experiments by checking the corneal or 
plantar nociception reflex and additional urethane was administered intravenously (i.v.) 
as necessary. The animals were spontaneously breathing through an intra-tracheal 
cannula. Catheters were inserted into both femoral arteries (for systemic arterial blood 
pressure measurement and for blood sampling) and into the left femoral vein (for drug 
administration). Body temperature was kept constant between 36.5–37.5 °C during the 
experiments using a heating pad controlled by a rectal probe. Systemic arterial pressure 
was recorded continuously on a polygraph (Model 7E, Grass, Quincy, MA, USA). 
Mice were anaesthetized by intraperitoneal injection of ketamine (100 mg kg
-1
) and 
xylazine (10 mg kg
-1
); the depth of anaesthesia was regularly checked during the 
experiments by observing the corneal or plantar nociception reflex and additional 
anaesthetics were administered intraperitoneally when necessary. The animals were 
spontaneously breathing. Body temperature was recorded by a rectal probe and kept 
constant between 36.5 – 37.5 °C during the experiments using a heating pad. 
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4.3.2. Measurement of Cerebrocortical Blood Flow 
Cerebrocortical blood flow (CoBF) was measured by laser-Doppler (LD) flowmetry. 
The head of the rat was fixed in a stereotaxic head holder with the nose 5 mm down 
from the interaural line. The skull of the parietal region was exposed and the bone was 
thinned over the parietal cortex on both sides with a microdrill, so that the lamina 
interna of the skull remained intact. Two LD probes were placed above the thinned skull 
at a 12° angle to the vertical to provide an optimal view of the cortex (4 mm caudal 
from bregma, 5 mm lateral from midline). LD flux (LDF) was measured with a two-
channel blood flow monitor (MBF3D, Moor Instruments, UK) and was recorded 
continuously. The LD monitor was calibrated before each individual experiment with a 
constant movement latex emulsion. The laser light was in the infrared range (780 nm) 
and penetrated about 1 mm into the brain covering approximately 7 mm
2
 of the parietal 
region, so that the data acquired mostly represented the characteristics of the blood flow 
in the parietal cortex. Blood pressure (BP) and CoBF were recorded continuously 
(BIOPAC Systems Inc, Goleta, CA, USA); the heart rate was calculated from the 
pulsating BP signal.  
4.3.3. Measurement of Vascular Tone 
The vascular tone of middle cerebral arteries (MCA) supplying the parietal cortex were 
measured in vitro. MCA segments were prepared from adult male Wistar rats sacrificed 
via exsanguination from the carotid arteries under deep ether anesthesia. The brains 
were removed and placed in ice-cold modified Krebs solution of the following 
composition (mM): NaCl, 119; KCl, 4.6; NaH2PO4· H2O, 1.2; CaCl2 · 2H2O, 1.5; 
MgCl2· 6H2O, 1.2; NaHCO3, 15; glucose, 10. Using a binocular microscope the middle 
cerebral artery and its large branches (201 ± 14 µm) were dissected and studied in a 
conventional myograph system (610M, Danish Myo Technology A/S, Aarhus, 
Denmark) [145]. The segments were transferred into 5-mL organ baths filled with 
modified Krebs solution and the bath solution was bubbled continuously with a 
humidified gas mixture (90 % O2/10 % CO2). The MCA segments were mounted on 2 
L-shaped tungsten wires (50-μm diameter): one wire was fixed to the bath, and the other 
was fixed to a force transducer. 
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4.3.4. Arterial Blood Gas Measurement 
Arterial blood gas and pH measurements were performed throughout the in vivo rat 
experiments by a Radiometer (Bronshoj, Denmark) ABL-77 analyzer and by the use of 
a capnograph (Capstar-100, CWE Inc., Ardmore, PA, USA). However, if the onset of 
capnography resulted in a more than 10 mmHg reduction of the arterial O2 tension, the 
device was disconnected and not used in that experiment. 
4.3.5. Infrared pulse oximetry 
Hair on a randomly selected thigh of each mouse was removed using Veet gel 
(Unilever, UK). Oxygen saturation, heart rate, breath rate and breath distension were 
measured continuously using MouseOX pulse oximeter (Starr Life Sciences Corp., 
Oakmont, PA, USA) in accordance with the manufacturer's instructions, and recorded 
using the MP100 system and AcqKnowledge 3.72 software from Biopac Systems Inc. 
(Goleta, CA, USA). Arterial O2 saturation values measured during the experiments were 
normalized to the O2 saturation determined 5 min before the administration of AM-404. 
4.4. Study Design 
4.4.1. Experiments to investigate the role of thromboxane receptors on cerebral 
vasomotion and CBF oscillations during NO-deficiency: 
In our in vivo rat experiments we have randomly assigned the animals into four 
experimental groups. In the control Group I. systemic and cerebral circulatory 
parameters, as well as blood gas and acid-base values were determined before as well as 
for 75 minutes after an i.v. bolus injection of 1 ml kg
-1
 vehicle (saline). Thereafter the 
animals received the thromboxane receptor agonist U-46619 in a dose of 1 mg kg
-1
 i.v., 
which in preliminary experiments was below the threshold of inducing any systemic or 
cerebral circulatory changes. Groups IIa., IIb. and IIc. received intravenously first NG-
nitro-L-arginine methyl ester (L-NAME) in a dose of 100 mg kg
-1
 for the inhibition of 
NO synthesis and 75 minutes later 1 mg kg
-1
 U-46619 (Group IIa.), saline (Group IIb.) 
or 10 mg kg
-1
 of the thromboxane synthase inhibitor ozagrel (Group IIc.). Previous 
studies have verified that L-NAME and ozagrel in the doses used in our present study 
effectively inhibit the activity of cerebral NO synthase and thromboxane synthase, 
respectively [146,147]. The final measurements were performed in all experimental 
groups 50 minutes after the administration of U-46619, saline or ozagrel. 
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The role of thromboxane receptors on cerebral vasomotion was also investigated in 
in vitro conditions. These experiments were performed on isolated MCA segments; first 
each segment was exposed to 124 mmol L
-1
 K
+
 Krebs solution to elicit a reference 
contraction. After a 30-minute resting period, the functional integrity of the endothelium 
was tested by application of bradykinin (0.01 to 10 mM) after precontraction induced by 
100 mM UTP. Segments that did not exhibit at least 20 % relaxation of the 
precontraction were considered to have damaged endothelium and were excluded from 
the study. After a 30-minute resting period, during which the baths were washed several 
times, the vessels received either 100 mM L-NAME in order to block NO synthesis or 
saline, the vehicle of L-NAME. Fifteen minutes later the effects of 100 nM U-46619 or 
10 nM endothelin-1 (ET-1) were determined on the vascular tension both in intact and 
NO synthase blocked vessels. The role of Rho – Rho-kinase signaling pathway was 
tested by administration of 10 mM Y-27632, a specific Rho-kinase inhibitor [148], to 
NO synthase blocked vessels showing stable vasomotion after administration of 
U-46619 or ET-1. In additional control experiments intact MCA segments were 
precontracted with 25 mmol L
-1
 K
+
 Krebs prior to administration of 100 nM U-46619. 
4.4.2. Experiments to address the role of endocannabinoids and Cannabinoid-1 (CB1) 
receptors in cerebrocortical blood flow regulation: 
In these studies, we have assigned each animal to one of the following experimental 
protocols; in the first protocol the influence of CB1 receptors on the CoBF under resting 
conditions was studied. After a 15-min baseline period one experimental group received 
1 ml vehicle (containing ethanol/emulphor/saline; 1:1:8; v:v:v); the other was treated 
with AM-251 (10 mg kg
-1
 i.v. [149]). Blood samples were taken before as well as 1, 2, 
4, 8, 16, and 32 minutes after the administration of AM-251 or its vehicle. The second 
protocol was designed to study the effects of enhanced endocannabinoid levels on the 
systemic and cerebrocortical circulation. Following baseline measurements, the animals 
received a single dose of 10 mg kg
-1
 AM-404 i.v. (dissolved in the same vehicle as AM-
251) in order to inhibit the reuptake of EC [88]. After blood pressure, CoBF, blood gas 
and acid-base parameters returned to their baseline levels, the animals were randomly 
divided into two experimental groups receiving intravenously either vehicle or 
10 mg kg
-1
 AM-251. Fifteen minutes later the administration of 10 mg kg
-1
 AM-404 
was repeated and the measurements were continued for an additional 45 min. With the 
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third protocol the role of CB1 receptors was studied during controlled 
hypoxia/hypercapnia (H/H), which was induced in a stepwise manner by the 
administration of different gas mixtures (10 % O2–10 % CO2–80 % N2 for producing 
mild H/H, 5 % O2–20 % CO2–75 % N2 for producing moderate H/H and 20 % CO2–
80 % N2 for producing severe H/H) with a constant flow of 3 L min
-1
 through a 5-ml 
open chamber connected to the trachea, at atmospheric pressure. CoBF was recorded 
continuously and its peak values were determined during the 8-min long steps of H/H. 
After the first mild, moderate and severe H/H challenge, the animals were randomly 
divided into two experimental groups receiving either vehicle or AM-251 (10 mg kg
-1
 
i.v.). Thirty minutes later the three steps of H/H were repeated in both groups and peak 
values were determined from the continuous recording of CoBF. 
4.4.3. Experiments to explore the role of endocannabinoids and Cannabinoid-1 (CB1) 
receptors in the respiratory regulation: 
Wild-type control and genetically modified CB1-KO mice were monitored and 
parameters of respiratory rate, heart rate, oxygen saturation and breath distension were 
collected for 10 minutes. Subsequently mice received a single dose of 10 mg kg
-1
 
AM-404 or its vehicle intravenously, and respiratory parameters were further recorded 
for 35 minutes [88].  
4.5. Analysis of Data 
The Discrete Fourier transform (spectrum) of the time series obtained in vivo (CoBF) or 
in vitro (vascular tone) was calculated by Fast Fourier Algorithm (FFT) [150]. The 
calculations were executed in the Matlab environment which uses an adaptive version of 
the FFT, called FFTW. The DC (zero frequency) component was eliminated from the 
spectrum by subtracting the mean value of time series from the samples and this way 
generating zero-mean time series. In order to identify the largest frequency component 
of the spectrum the region of interest was gated by an appropriate frequency window. 
Statistical analysis was performed using the GraphPad Prism software v.6.07 from 
GraphPad Software Inc. (La Jolla, CA, USA). Values are presented as mean ± SEM; n 
represents the number of experiments. Statistical analysis was performed using two-way 
ANOVA for repeated measurements followed by Bonferroni post-hoc test. A p value of 
less than 0.05 was considered to be statistically significant.  
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5. Results 
5.1. Hypersensitivity to Thromboxane Receptor Mediated Cerebral 
Vasomotion and CBF Oscillations during Acute NO-Deficiency in Rats 
5.1.1. Activation of thromboxane receptors under physiological conditions have no 
effect on systemic physiological parameters or on cerebrocortical blood flow 
In order to characterize the significance of TP-receptor activation in promoting CBF 
oscillations, we first investigated the effect of the TP-receptor agonist U-46619 in a 
dose of 1 µg kg
-1
 during physiological conditions. Baseline physiological parameters 
before administration of 100 mg kg
-1
 L-NAME or its vehicle, saline, were found to be 
within the normal range in all in vivo experimental groups (Table 7.); furthermore, 
neither i.v. administration of the solvent (saline) nor that of the agonist U-46619 
induced any significant changes in acid-base, blood gas or systemic circulatory 
parameters in the control Group I. (data not shown). Additionally, neither the average 
CoBF nor its Fourier spectrum changed after the administration of saline or U-46619 in 
this experimental group (data not shown). These observations confirmed that 
administration of 1 µg kg
-1
 U-46619 has no significant effect on the systemic and 
cerebrocortical circulation under physiological conditions. 
Table 7. Baseline physiological parameters in the different in vivo experimental groups. 
[132]. Values are mean ± SEM (n = 7, 10, 6 and 7 in Groups I, IIa., IIb. and IIc., 
respectively)  
MEASURED VARIABLE 
EXPERIMENTAL GROUP 
I. IIa. IIb. IIc. 
Mean Arterial Pressure (mmHg) 97.9 ± 2.4 100.0 ± 2.9 97.7 ± 3.5 107.7 ± 4.0 
Heart Rate (bpm) 410 ± 9 408 ± 15 413 ± 8 435 ± 20 
PaCO2 (mmHg) 41.0 ± 2.6 43.7 ± 1.5 38.2 ± 1.6 40.0 ± 2.0 
O2 Sat (%) 96.5 ± 0.5 96.5 ± 0.5 96.6 ± 0.3 96.2 ± 0.3 
pH 7.34 ± 0.01 7.32 ± 0.02 7.38 ± 0.01 7.37 ± 0.01 
Standard Base Excess (mmol/l) -3.7 ± 1.1 -2.2 ± 0.7 -2.6 ± 0.4 -1.7 ± 1.1 
5.1.2. NO synthase blockade increases mean arterial pressure, while decreases heart 
rate and cerebrocortical blood flow 
In Groups IIa., IIb. and IIc. we have mimicked the pathophysiological state of 
NO-deficiency by pharmacologically inhibiting NOS activity with 100 mg kg
-1
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L-NAME. In this challenged state, we have observed no significant changes in acid base 
or blood gas parameters but we have seen increased systemic blood pressure and 
decreased heart rate (Figure 4). These changes developed within 25 minutes after 
L-NAME administration and remained unaltered later even after the intravenous 
administration of 1 µg kg
-1
 U-46619 (in Group IIa.), 1 ml kg
-1
 saline (in Group IIb.) or 
10 mg kg
-1
 ozagrel (in Group IIc.) (data not shown). The CoBF reduced by more than 
25 % within the first 25 min after L-NAME administration (Figure 4) but did not 
change further until the completion of the experiments in any of these experimental 
groups (data not shown).  
 
Figure 4. NO synthase blockade increases mean arterial pressure (MAP), while 
decreases heart rate (HR) and cerebrovascular blood flow (CBF) [132]. Data are 
shown as mean ± SEM, values are normalized to the steady-state pre-injection values 
and presented as percentual changes (n = 10, 6 and 7 in case of MAP and HR and n = 
20, 12 and 14 in case of CoBF in Groups IIa., IIb., IIc., respectively). 
 
5.1.3. Activation of thromboxane receptors aggravates while inhibition of TXA2 
synthesis attenuates vasomotion in the absence of NO 
Low frequency CoBF oscillations (4-12 cycles min
-1
 ), which were absent under resting 
conditions, developed after the administration of L-NAME with a dominant frequency 
of 148 ± 2 mHz and peak magnitude of 5.6 ± 0.5 AU (n =46). U-46619 significantly 
increased while ozagrel decreased the amplitude of these oscillations without changing 
the dominant frequency (Figure 5A and C, respectively.). In contrast, saline, the vehicle 
of U-46619 and ozagrel, failed to induce any changes in the magnitude or frequency of 
CoBF oscillations (Figure 5B). 
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Figure 5. Activation of thromboxane receptors aggravates while inhibition of TXA2 
synthesis attenuates CoBF oscillations developed in the absence of NO. A-C: 
Original recordings of the cerebrocortical laser-Doppler flux in vivo before (left panels) 
and after (right panels) administration of the TP-receptor agonist U-46619 (A), the 
thromboxane synthase inhibitor ozagrel (C) or their vehicle (saline) (B) in rats 
pretreated by the NO synthase inhibitor L-NAME. D: Quantitative analysis of slow 
wave oscillations with discrete Fourier transformation. The peak magnitudes of the 
power spectra are compared before and after treatments in the three experimental groups 
[132]. Values are mean ± SEM (n = 20, 12 and 14 in Group IIa, IIb, and IIc, 
respectively) *p<0.05 versus ‘‘Before Treatment’’. 
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5.2. Role of Endocannabinoids and Cannabinoid-1 Receptors in 
Cerebrocortical Blood Flow Regulation 
5.2.1. Inhibition of tonic endocannabinoid release and constitutive Cannabinoid-1 
receptor activity have no effect on systemic blood pressure and cerebrocortical blood 
flow 
To evaluate the potential influence of tonic EC release and constitutive CB1 receptor 
activity under resting conditions, blood pressure and CoBF were measured after i.v. 
administration of the selective CB1 antagonist/inverse agonist AM-251, and were 
compared to vehicle treated animals. Neither 10 mg kg
-1
 AM-251 nor its vehicle 
induced any significant change in mean arterial blood pressure (MAP, Figure 6A) or 
CoBF (Figure 6B) up to 32 minutes after their application. Heart rate, arterial blood gas 
tensions, acid-base parameters and hematocrit remained unchanged during the 
observation period (Table 8). These observations indicated that under physiological 
conditions, constitutive CB1-activity has no significant influence on systemic and 
cerebrocortical circulation. 
 
Figure 6. The effects of CB1 receptor blockade on mean arterial pressure (A) and 
cerebrocortical blood flow (B). Mean arterial pressure (MAP, n = 10) and 
cerebrocortical blood flow (CoBF, n = 20) are shown before (0 min) as well as 1, 2, 4, 
8, 16 and 32 minutes after intravenous administration of 10 mg kg
-1
 AM-251 () or its 
vehicle () in urethane-anaesthetized rats [140]. Values are presented as mean ± SEM. 
AU, arbitrary unit. 
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Table 8. Physiological parameters before (0 min) and at several timepoints after the 
administration of AM-251 or its vehicle [140]. Values are expressed as mean ± SEM (n 
= 22 and 18, in Vehicle and AM-251 treated group, respectively) 
MEASURED 
VARIABLE 
TREATMENT 0 MIN 1 MIN 2 MIN 4 MIN 8 MIN 16 MIN 32 MIN 
Heart Rate (bpm) 
Vehicle 420 ± 
10 
402 ± 
7 
404 ± 
7 
404 ± 
8 
413 ± 
10 
423 ± 
10 
396 ± 
16 
 
AM-251 411 ± 
11 
384 ± 
10 
379 ± 
12 
377 ± 
10 
385 ± 
10 
404 ± 
9 
407 ± 
12 
pH 
Vehicle 7.40 ± 
0.01 
7.37 ± 
0.01 
7.37 ± 
0.01 
7.38 ± 
0.01 
7.39 ± 
0.01 
7.40 ± 
0.01 
7.41 ± 
0.01 
 
AM-251 7.40 ± 
0.01 
7.40 ± 
0.01 
7.41 ± 
0.01 
7.42 ± 
0.02 
7.42 ± 
0.02 
7.40 ± 
0.01 
7.41 ± 
0.01 
PaO2 (mmHg) 
Vehicle 87.7 ± 
2.0 
76.3 ± 
3.2 
76.5 ± 
2.7 
79.0 ± 
2.7 
78.4 ± 
2.7 
81.3 ± 
3.2 
80.2 ± 
3.2 
 
AM-251 83.6 ± 
2.0 
82.3 ± 
6.5 
85.8 ± 
2.1 
86.9 ± 
1.8 
85.4 ± 
2.7 
84.4 ± 
2.0 
84.4 ± 
2.0 
PaCO2 (mmHg) 
Vehicle 42.7 ± 
1.0 
43.5 ± 
1.0 
43.0 ± 
0.9 
41.8 ± 
1.2 
40.4 ± 
1.1 
39.6 ± 
1.3 
38.1 ± 
1.7 
 
AM-251 40.4 ± 
1.5 
40.2 ± 
1.2 
37.3 ± 
1.7 
36.8 ± 
2.2 
35.7 ± 
1.6 
37.4 ± 
1.2 
38.7 ± 
1.4 
O2 Saturation (%) 
Vehicle 96.5 ± 
0.2 
93.8 ± 
0.9 
94.2 ± 
0.7 
94.8 ± 
0.5 
95.0 ± 
0.6 
95.5 ± 
0.6 
95.6 ± 
0.6 
 
AM-251 96.2 ± 
0.3 
95.2 ± 
0.7 
96.5 ± 
0.3 
96.7 ± 
0.3 
96.5 ± 
0.4 
96.3 ± 
0.3 
96.3 ± 
0.4 
SBE (mmol/l) 
Vehicle 1.2 ± 
0.4 
0.1 ± 
0.4 
-0.3 ± 
0.4 
-0.6 ± 
0.4 
-0.2 ± 
0.5 
-0.1 ± 
0.5 
-0.5 ± 
0.6 
 
AM-251 0.1 ± 
0.7 
-0.6 ± 
0.5 
-0.9 ± 
0.5 
-0.8 ± 
0.4 
-1.3 ± 
0.3 
-1.3 ± 
0.4 
-1.2 ± 
0.3 
Hematocrit (%) 
Vehicle 45.8 ± 
1.1 
44.1 ± 
1.1 
43.4 ± 
0.9 
43.4 ± 
1.2 
42.9 ± 
0.8 
43.5 ± 
1.2 
42.1 ± 
1.0 
 
AM-251 42.8 ± 
1.3 
40.5 ± 
1.0 
41.0 ± 
0.8 
42.6 ± 
1.2 
42.9 ± 
0.9 
41.9 ± 
1.3 
41.1 ± 
1.9 
 
5.2.2. Tri-phasic effect of enhanced endocannabinoid release: the initial hypertension 
and increase in cerebrocortical blood flow is followed by sustained hypotension and 
decrease in cerebrocortical blood flow 
First we tested the effect of enhanced endocannabinoid release on blood pressure and 
CoBF. Baseline physiological parameters were within normal range in the absence and 
presence of AM-251 before AM-404 treatment (Table 9). After the i.v. administration 
of 10 mg kg
-1
 AM-404, a cannabinoid reuptake inhibitor, we observed three distinct 
phases of BP and CoBF. Phase I consisted of marked hypertension (Figures7A and 8A) 
accompanied by a significant increase of CoBF (Figures 7B and 8B) with minor 
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changes in arterial blood gas tensions and pH (Figure 9). The BP and CoBF elevations 
reached their maximum within 0.5 min and thereafter started to return towards their 
baseline levels until the onset of the second phase with a delay of 1–2 min. During 
phase II CoBF has increased most prominently with a peak at 3.5 min after 
administration of AM-404 (Figures 7B and 8B), accompanied by increased levels of 
expired CO2 (Figure 7C) and BP (Figures 7A and 8A). Blood gas analysis revealed 
marked hypoxia (Figures 9A and 9C), hypercapnia (Figure 9B) and acidosis (Figure 
9D), and therefore, changes in the CoBF and BP were considered to be secondary to the 
depression of respiration. The third phase of changes was dominated by sustained 
hypotension (Figures 7A and 8A), which reached its maximum at 20 min. During this 
phase the arterial oxygen tension and saturation normalized (Figures 9A and 9C), 
whereas the hypercapnia observed in phase II was reverted to a slight hypocapnia 
(Figure 9B), and the acidic arterial pH returned towards the physiological level (Figure 
9D). Interestingly, CoBF showed a significant decrease during phase III (Figure 8B), 
which was attributed to the reduction of the MAP and the arterial CO2-tension (PaCO2). 
BP and CoBF returned to their baseline levels within 45 min after the administration of 
AM-404.  
 
Table 9. Baseline physiological parameters before the administration of AM-404 in the 
absence and presence of AM-251 [140]. Values are presented as mean ± SEM (n = 10) 
*p<0.05 versus ‘‘Before AM-251’’ 
MEASURED VARIABLE BEFORE AM-251 AFTER AM-251 
MAP (mmHg) 112.8 ± 6.5 103.8 ± 3.0 
CoBF (AU) 346.2 ± 28.5 362.1 ± 28.7 
PaO2 (mmHg) 86.0 ± 2.9 76.9 ± 2.8 * 
PaCO2 (mmHg) 44.8 ± 1.7 38.5 ± 1.5 * 
O2 Saturation (%) 95.9 ± 0.6 94.6 ± 0.6 * 
pH 7.38 ± 0.01 7.38 ± 0.01 
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Figure 7. Representative recordings of the effects of endocannabinoid reuptake 
inhibition on blood pressure (A), cerebrocortical blood flow (B) and expired CO2 
levels (C). After the intravenous administration of 10 mg kg
-1
 AM-404 a transient 
increase in blood pressure (BP) and cerebrocortical blood flow (CoBF) can be seen 
(phase I). It is followed by a second prominent increase in CoBF (phase II) that is 
accompanied with a rise of expired CO2. Thereafter a sustained decrease in the BP and 
CoBF can be seen (phase III). The arrows indicate the injection of AM-404 [140].  
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Figure 8. Effects of AM-404 on mean arterial pressure (A) and cerebrocortical 
blood flow (B) before and after AM-251 treatment. Changes in mean arterial 
pressure (MAP, n = 10) and cerebrocortical blood flow (CoBF, n = 20) are shown in 
phases I, II and III of the AM-404 (10 mg kg
-1
, i.v.) response before and after treatment 
with AM-251 (10 mg kg
-1
, i.v.) [140]. Values are shown as mean ± SEM and are 
expressed as changes from baseline (see Table 9); *p<0.05, **p<0.01, versus ‘‘Before 
AM-251’’.  
 
After testing the effect of enhanced endocannabinoid release on blood pressure and 
CoBF, we inhibited CB1 receptors to assess their involvement in the mediation of 
effects induced by inhibition of EC reuptake. Animals were pretreated with 10 mg kg
-1
 
AM-251 or its vehicle, and the administration of AM-404 and subsequent 
measurements were repeated. During phase I the increase of MAP was comparable 
between the control and CB1-blocked group (Figure 8A), indicating that CB1 receptors 
are not involved in the transient hypertension induced by enhanced EC levels. However, 
the increase of the CoBF attenuated significantly in the presence of AM-251 
(Figure 8B), implying an improved autoregulation of the cerebral circulation. 
Administration of AM-251 markedly attenuated hypoxia and hypercapnia as well as the 
acidosis seen during phase II (Figure 9), indicating that the increased EC availability 
after AM-404 suppresses respiration via CB1 receptor activation. The mild hypertension 
observed during phase II, and interestingly the increase of CoBF were both resistant to 
AM-251 treatment (Figure 8), which is surprising if we consider that changes in blood 
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gas and pH levels were both abolished by CB1 receptor inhibition. Therefore, we 
hypothesized that in addition to suppressing EC-induced hypoventilation, AM-251 
enhanced the reactivity of the cerebrocortical circulation to H/H (further discussed in 
6.2.2). Finally the sustained hypotension seen during phase III was attenuated after 
AM-251 treatment (Figure 8A), indicating the involvement of CB1 receptors in 
mediating the effects of elevated EC levels. The accompanying changes in arterial O2 
tension and saturation as well as the pH were not affected by CB1-blockade, although 
the mild hypocapnia was attenuated (Figure 9). 
 
 
Figure 9. Effects of AM-404 on arterial blood gases and pH before and after 
AM-251 treatment. Arterial blood-gas and pH changes are shown in phases I, II and III 
of the AM-404 (10 mg kg
-1
, i.v.) response before and after treatment with AM-251 
(10 mg kg
-1
, i.v.) [140]. Values are shown as mean ± SEM and are expressed as changes 
from baseline (see Table 9); *p<0.05, **p<0.01, versus ‘‘Before AM-251’’, n = 10.  
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5.3. CB1 Receptor-mediated Respiratory Depression by Endocannabinoids  
5.3.1. Enhanced endogenous cannabinoid levels induce transient respiratory depression 
and consequent arterial hypoxia in a CB1-dependent manner  
Respiratory parameters were within physiological range in both wild-type control and 
CB1-KO mice. Intravenous administration of 10 mg kg
-1
 AM-404, which inhibits EC 
reuptake, thus enhancing regional EC levels, induced a transient depression in oxygen 
saturation (Figure 10A) and respiration rate (Figure 10B) and a concomitant increase in 
breath distension (Figure 10C) in control mice. Administration of the solvent alone had 
no effect (data not shown). The rapid onset of respiratory depression started within 1 
minute after treatment with AM-404, and reached its maximal level within 4 min, 
whereas its recovery started after 8 minutes; respiratory parameters gradually recovered 
to normoxic levels that was completed within 16 minutes. The recovery of oxygen 
saturation in AM-404 treated wild-type control mice was not complete within the 
measured experimental period; however, a gradual decrease in the oxygen saturation 
correlating with the time of anaesthesia could be observed in the vehicle treated control 
mice (data not shown) and AM-404 treated CB1-KOs (Figure 10A), thus it was 
considered an endocannabinoid independent effect. Additionally, there was a 
simultaneous increase in breath distension during respiratory depression in wild-type 
control animals (Figure 10C), indicating that the lower respiratory rate was associated 
with larger fluctuations in the central venous pressure and cardiac output. Changes in 
heart rate were generally unaltered upon AM-404 administration, and were not further 
analyzed. In contrast to AM-404 evoked respiratory depression in wild-type control 
mice, CB1-KO mice showed no reduction in oxygen saturation (Figure 10A) and 
respiration rate (Figure 10B); accompanying changes in breath distension were also 
absent (Figure 10C). 
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Figure 10. Effect of AM-404 administration on oxygen saturation (A), breath rate 
(B) and breath distension (C). Representative recordings in wild-type control animals 
(left panels) and averaged results of multiple experiments in wild-type control () and 
CB1-KO () mice (right panels) of oxygen saturation (A), respiratory rate (B) and 
breath distension (C) as a function of time. Administration of AM-404 (10 mg kg
-1
, iv.) 
is indicated by arrows on original recordings. Physiological parameters were determined 
before (0 min.) and at 1, 2, 4, 8, 16, and 32 minutes after AM-404 for statistical analysis 
(right panels) [143]. Values are presented as mean ± SEM; n= 6-6 in the case of O2 
saturation and 4-4 in the case of respiratory rate and breath distension measurements; 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 control versus KO, #p<0.05, ##p<0.01, 
###p<0.001, ####p<0.0001 versus “0 min”.  
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6. Discussion 
6.1. Hypersensitivity to Thromboxane Receptor Mediated Cerebral 
Vasomotion and CBF Oscillations during Acute NO-Deficiency in Rats 
Cerebral vasomotion, the low frequency fluctuation of the cerebral oxygen availability, 
independent of the cardiac and respiratory cycles, often accompanies pathological 
incidents, such as SAH, but its relevance and the underlying mechanism is largely 
unresolved. Our results demonstrate that vasomotion and CBF oscillation during 
NO-deficiency are enhanced by TP-receptor activation [151]. Numerous pathological 
condition has been associated with impaired NO release, such as atherosclerosis, 
diabetes, hypertension, ischemia and SAH. Reduction in the availability of NO under 
these pathological conditions often accompanies with increased platelet aggregation as 
well as activation of TP-receptors and consequently the release of TXA2. The 
experimental model applied in the present study resembles the features of several 
cerebrovascular diseases.  
During NO-deficiency, ozagrel inhibited L-NAME induced CoBF oscillations 
indicating the involvement of endogenous TXA2; however, in order to comprehensively 
understand the underlying intracellular mechanism, the in vitro effect of the TP-receptor 
agonist U-46619 was tested first on isolated MCA. In accordance with the in vivo effect 
of TP-receptor activation, the administration of 100 nM U-46619 induced a slight 
(10.9 ± 5.3 %) vasoconstriction, while its vehicle, saline, had no effect on the mean 
vascular tension; furthermore, no vasomotional activity could be observed in the 
isolated vessels before or after saline or U-46619, suggesting that TP-receptor activation 
under physiological conditions fails to induce vasomotion. To resemble the 
NO-deficient pathophysiological conditions, NO synthesis was inhibited with L-NAME 
in isolated MCA. In the absence of NO the vascular tone was slightly increased (by 
9.5 ± 2.2 %) but did not induce vasomotion; however, the subsequent stimulation of the 
TP-receptors elicited strong elevation of the mean vascular tone (by 77.2 ± 6.2 %) as 
well as vasomotion could be observed in 16 out of 19 NOS-blocked MCA with a 
dominant frequency of 56.1 ± 4.7 mHz. Quantitative analysis of the peak magnitude of 
the Fourier spectra showed a 5.35-fold increase after administration of U-46619 
(Figure 11A). To rule out the possibility that the evoked vasomotional activity was due 
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to the increased vascular tension, control vessels were immersed in Krebs solution 
supplemented with 25 mM K
+
 prior to treatment with U-46619. Although the mean 
vascular tension was comparable to that of L-NAME + U-46619 treated (62.3 ± 8.1 % 
vs. 77.2 ± 6.2 %), no vasomotional activity could be observed in any of the tested 
vessels [132].  
As shown previously [152], inhibition of the NO pathway causes vasoconstriction and 
reduction in cerebral blood flow. This implies that in the cerebral circulation, 
constitutive NO-synthesis is necessary to maintain resting basal tone by suppressing 
TXA2 synthesis and release [152]. Desensitization of TP-receptors occurs through 
phosphorylation at Ser
331
 by cyclic GMP-dependent kinase (PKG) [153]; however, 
NO-deficiency also impairs the signaling pathway that couples TP-receptor activation to 
smooth muscle contraction. As shown previously, TXA2 is involved in both Gq/11 and 
G12/13 mediated vasoconstriction [154,155]; NO reportedly interacts with G12/13 pathway 
mediated calcium sensitization via PKG mediated RhoA [156] and telokin [157] 
inhibition as well as PKG directly phosphorylates myosin phosphatase targeting subunit 
(MYPT1) at Ser
695
, resulting in decreased phosphorylation on the adjacent inhibitory 
Thr
696
 site [158,159]. Hence, during NO-deficiency, not only TP-receptors, but also 
downstream signaling pathways are released from tonic inhibition making vascular 
smooth muscle sensitive to calcium waves, consequently vasoconstriction. To test this 
hypothesis, NOS blocked vessels showing vasomotion after U-46619 administration, a 
specific Rho-kinase inhibitor, Y-27632, was administered to explore the involvement of 
Rho-kinase in the mediation of the vascular responses. Treatment with 10 µM Y-27632 
abolished the vasoconstriction and vasomotion (Figure 11), suggesting that besides 
TXA2, other G12/13 -dependent activator metabolites are involved in the appearance of 
CoBF oscillations, since inhibition of thromboxane synthesis only partially abolished 
CoBF oscillations in vivo, while blockade of Rho-kinase suppressed completely the 
vasomotional activity in isolated vessels. In addition, in vitro treatment with 
endothelin-1 (ET-1), which also acts through the RhoA – Rho-kinase dependent 
pathway in the cerebrovascular bed, evoked vasomotion with a dominant frequency of 
48.8 ± 7.3 mHz. The augmentation in the magnitude of the Fourier spectra was 
equivalent to the increase observed upon TP-receptor activation, which effect was 
completely abolished after Rho-kinase inhibition (Figure 11B). 
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In conclusion, pharmacological inhibition of endogenous TXA2 production or the 
prevention of TP-receptors hypersensitivity during NO-deficiency abrogates the 
enhanced vascular reactivity; potentially forestalling the appearance of vasospasm, 
resulting in better outcome after subarachnoid hemorrhage. 
 
Figure 11. Activation of thromboxane or endothelin receptors induce Rho-kinase 
dependent vasomotion in NO synthase blocked MCA. Quantitative analysis of slow 
wave oscillations with discrete Fourier transformation in L-NAME treated vessels 
before and after the administration of the TP-receptor agonist U-46619 (A) or 
endothelin-1 (B) followed by the Rho-kinase inhibitor Y-27632 [132]. Values are 
presented as mean ± SEM fold changes of the peak magnitudes of the power spectra 
compared to the baseline. *p<0.05, ***p<0.001 versus L-NAME, ##<0.01 versus ET-1 
and ###<0.001 versus U-46619 (n = 10–20).   
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6.2. Role of Endocannabinoids and Cannabinoid-1 Receptors in 
Cerebrocortical Blood Flow Regulation 
The effect of endocannabinoids on the cardiovascular system has been extensively 
studied. Endocannabinoids are involved in the regulation of systemic blood pressure, 
cardiac output and vascular resistance [23,160,161]. Acute use of marijuana induces 
tachycardia in humans, while chronic consumption leads to hypotension and 
bradycardia [162,163]. In mice and rats, potent cannabinomimetics induce CB1 receptor 
mediated bradycardia, hypotension and depressed cardiac contractility; effects that are 
partially contributed to the decrease of norepinephrine release from sympathetic nerve 
terminals and also direct action on the vasculature and myocardium [161]. However, 
published data on the cerebrovascular effect of the endocannabinoid system are 
controversial. Elevated CBF has been reported in marijuana smoking humans that 
directly correlated with plasma Δ9-THC levels [142]. Similarly, cannabinomimetics 
increased the cerebral blood perfusion in dogs, humans [137,164], and in anesthetized 
rats [139]. Conversely, conscious rats showed reduction in CBF after anandamide 
treatment [138]. These various observations can be attributed to the diverse expression 
of cannabinoid receptors, and additionally to the wide variety of mechanisms by which 
endocannabinoids are able to influence the regulation of the cerebrovascular tone. The 
cerebral vasculature responds with vasodilatation to CB1 receptor stimulation [110], 
however, cannabinoid receptors on the neurons act as modulators of the synaptic 
transmission, thereby adjusting the cerebral metabolic demand, and consequently 
decreasing CBF indirectly [23]. Considering that the observed effects were of 
exogenously applied phyto- or endocannabinoids that does not necessarily reproduce 
physiological conditions, a different approach was used in the current study, where the 
endocannabinoid system activity was enhanced by administration of the cannabinoid 
reuptake inhibitor, AM-404. 
6.2.1. Influence of constitutive endocannabinoid release and CB1 receptor activation on 
systemic and cerebrocortical circulation 
The constitutive activity of CB1 receptors has been reported in various studies [165]. 
Therefore, to study the involvement of constitutive CB1 receptor activity on the 
cerebrovascular circulation, an inverse agonist/antagonist, AM-251, was tested under 
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physiological conditions. Administration of 10 mg kg
-1
 AM-251 that had been shown 
previously to effectively inhibit CB1 receptor activity in vivo [149], failed to induce any 
significant changes in the observed systemic and cerebral circulatory parameters, 
suggesting the absence of constitutive influence of CB1 receptors on the cardiovascular 
system under physiological conditions. This finding is in accordance with reports on 
CB1 receptor knockout mice [166], although neither the data presented in the current 
study nor the published results exclude the possible involvement of several backup 
regulatory mechanisms that may take over the function of CB1 receptor mediated 
pathways in case of pharmacological blockade or genetic absence.  
6.2.2. Influence of enhanced endocannabinoid levels and consequent CB1 receptor 
activation on systemic and cerebrocortical circulation 
To test the effect of increased EC levels on the systemic and cerebrocortical circulation, 
AM-404, a cannabinoid reuptake inhibitor, was administered and subsequent changes 
were recorded. Although the exact mechanism of action of AM-404 has been debated, 
while it is not solely involved in the inhibition of cellular uptake, but is also a substrate 
for fatty acid amide hydrolase [167] as well as a transient receptor potential vanilloid 
type-1 (TRPV1) channel activator [168], it has been shown to increase the endogenous 
levels of anandamide in the brain [88]. Three different phases of systemic and cerebral 
circulatory responses could be distinguished after administration of 10 mg kg
-1
 
AM-404. 
Phase I consisted of a transient hypertension, consistent with published results after i.v. 
anandamide administration in mice [105] and rats [169,170], indicating that EC 
enhancement via reuptake inhibition recapitulate the previously observed effect of 
anandamide to elevate the blood pressure. However, the transient hypertension was 
resistant to CB1 receptor inhibition, indicating that this phenomenon is not mediated by 
CB1 recptors. Similar observations were reported in TRPV1-receptor deficient mouse 
model [105], proposing, together with the published observation of anandamide 
mediated TRPV1 activation [171], the most likely mechanism behind the transient 
hypertension. Accompanying the increase in mean arterial pressure, CoBF also 
increased markedly, probably due to the hypertension exceeding the upper limit of 
cerebral autoregulation. However, CB1 receptor inhibition resulted in significant 
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reduction of the cortical hyperemia, indicating an influence of CB1 receptors on the 
autoregulation of cerebral circulation. 
During phase II, pronounced respiratory depression was observed leading to changes of 
the arterial blood gas tensions and pH, consequently increasing CoBF. The respiratory 
changes were sensitive to CB1 receptor inhibition, consistent with a previous study 
using AM-281 after anandamide treatment in rats [122], as well as the respiratory 
depression induced by synthetic CB1 agonists WIN-55212-2 and CP-55940 that could 
be blocked by SR-141716A [119]. Injection of WIN-55212-2 to the cisterna magna or 
rostral ventrolateral medulla oblongata [120,124] of rats suppressed respiration 
suggesting that central CB1 receptors negatively modulate respiratory control circuits. 
The marked increase in CoBF accompanying the respiratory changes was surprisingly 
resistant to CB1 receptor inhibition, although AM-251 suppressed arterial blood gas and 
pH changes related to enhanced EC levels. In order to explain this discrepancy, the 
possible involvement of AM-251 in the enhancement of CoBF reactivity was 
hypothesized. To determine the involvement of CB1 receptors during the respiratory 
depression and their effect on the CoBF, closely regulated hypoxia and hypercapnia 
were induced and changes in the CoBF were evaluated before and after AM-251 
administration. This experimental setup allowed us to observe the influence of CB1 
receptor inhibition on the CoBF independent of the blood gas changes, while they were 
kept constant and changes secondary in nature to the respiratory depression could be 
ruled out. In our study we have shown that inhalation of three different gas mixtures, 
which induced reproducible degree of mild or moderate hypoxia and hypercapnia, 
CoBF elevation was amplified (by 28.1 ± 8.8 % and 39.4 ± 10.0 %, respectively) 
whereas the peak CoBF during severe H/H was unaffected after treatment with AM-251 
compared to its control (Figure 12B). 
It has been shown that cerebrovascular CB1 receptors have vasodilatory influence on 
cerebral vessels [110], suggesting the involvement of receptors extravascular in nature; 
both neurons and astrocytes express CB1 receptors [172,173], regulating neuronal NOS 
activity and influencing vascular tone. KCl-induced neuronal NOS activity is impaired 
in the presence of CB1-agonists in cerebellar granule cells without influencing basal 
NO-production [174]. However, pertussis toxin or SR141716A treatment reversed the 
effect of CB1-activation and increased NO production that was additive with KCl 
DOI:10.14753/SE.2017.2102
56 
 
stimulation [174]. It has also been published that CB1 receptors have inhibitory effect 
on the metabolic activity of neurons and astrocytes [175], consequently influencing 
release of NO and vasoactive metabolites. Furthermore, the H/H-induced 
cerebrovascular responses involve perivascular sympathetic nerves [176,177] that are 
modulated by the EC system [178].  
Although the exact mechanism of the CB1 receptor involvement in H/H-induced 
cerebrocortical hyperemia is unclear, the presented results support that during mild and 
moderate H/H, inhibition of CB1 receptors enhanced CoBF responses, indicating that 
EC system has an inhibitory role in H/H induced vasorelaxation.  
Phase III could be characterized with a sustained hypotension, in agreement with 
published data describing the sustained hypotensive effect of phyto- and 
endocannabinoids [179], as well as synthetic analogues [133], although the receptor 
involved mediating this effect is unclear. AM-251 treatment decreased the reduction in 
blood pressure, however, did not completely abolish it, suggesting that CB1 receptors 
are involved, but not the sole receptors mediating the depressor effect of AM-404. 
During this phase, reduction in CoBF could be observed, most likely due to the decrease 
in the arterial CO2-tension as well as the reduction of the mean arterial blood pressure 
close to the lower limit of cerebral autoregulation. The attenuation of hypocapnia 
observed after AM-251 treatment is most likely due to the decrease of respiratory 
depression found during phase II, nevertheless, the possibility that CB1 receptor 
inhibition influenced cerebral autoregulation at lower BP levels cannot be excluded. 
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Figure 12. Cerebrocortical blood flow and arterial blood gas tensions during 
stepwise hypoxia/hypercapnia. Cerebrocortical blood flow (A and B, expressed as 
percentage of baseline levels) and arterial blood-gas tensions (C and D) are shown 
before (Baseline) and during mild, moderate and severe hypoxia/hypercapnia before 
() and after () intravenous injection of 10 mg kg-1 AM-251 or its vehicle [140]. 
Values are mean ± SEM, *p<0.05, **p<0.01 versus ‘‘Before AM-251’’, n = 4–12. 
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6.3. CB1 Receptor-mediated Respiratory Depression by Endocannabinoids  
Previous studies utilized exogenous cannabinomimetics to investigate the role of 
cannabinoids and endocannabinoids in the physiological control of respiration; 
however, this approach may not necessarily mimic the physiological stimulation of the 
EC system. Compared to previous studies, the administration of a cannabinoid reuptake 
inhibitor, AM-404, at a concentration shown previously to enhance ECs [88] has 
enabled us to analyze the effect of the activated EC system on the regulation of 
respiration by more closely modeling the physiological concentration and distribution of 
ECs. Administration of AM-404 to wild-type control mice induced a rapid, transient 
reduction in respiratory rate and oxygen saturation; in agreement with previous 
published results, where intracisternal [124] or intramedullar [120] injection of 
WIN55212-2, a synthetic CB1 and CB2 receptor agonist, induced reduction in 
respiratory rate and minute volume, and an increase in tidal volume. The recent and 
previous findings implicate a pivotal role for the cannabinoid receptors located in the 
brainstem in the control of respiration. 
Concomitant to the activated EC system evoked respiratory depression; a simultaneous 
increase in breath distension was present in wild-type mice. Breath distension reflects 
the change in blood volume in peripheral vessels that are due to local blood pressure 
changes generated by the fluctuation of intrathoracic pressure associated with breathing 
[180], and is generally considered as an indicator of increased breathing effort 
[181,182]. Cannabinoids have been shown to induce bronchodilation [183,184], 
suggesting that the accompanying increase in breath distension during elevation of EC 
levels is not the result of the increased airway resistance; instead it correlates with 
increased respiratory workload, particularly deeper breath intake. Additionally, previous 
studies also reported increased tidal volume during EC administration [124]. Hence, the 
displayed changes in breath distension in wild-type control mice are most likely a 
compensatory mechanism to counteract the strong reduction in breath rate [143]. 
Albeit our previous work [140] lacked direct evidence proving conclusively the 
involvement of endogenously released ECs in the control of breath regulation; 
analyzing the effects of the elevated EC system in mice proved critical to 
unambiguously demonstrate the involvement of CB1 receptors in the respiratory 
regulation. Indeed, administration of AM-404 in a dose that has been shown to increase 
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endogenous cannabinoid levels [88], recapitulated the transient respiratory depression in 
wild-type control mice [143]. Treatment of genetically modified animals lacking the 
CB1 gene (CB1-KO) with AM-404, to enhance the EC-system, failed to demonstrate 
suppression of breath rate and also did not show the consequent reduction in oxygen 
saturation. Conclusively, the lack of the respiratory depression in CB1-KO mice 
indicates that the presence of CB1 receptors is integral to the observed effects. 
The importance of phyto- and endocannabinoids are increasing in the medicinal 
treatment of acute and chronic pain, diabetes and obesity, cerebral ischaemia, epilepsy, 
cancer and inflammation, but the medical application is severely thwarted by adverse 
side effects [185,186]. Acute application induces elevation in heart rate, as well as 
decrease in subjective alertness and a decrease in motor stability [185]; chronic usage 
has reportedly led to increased prevalence of respiratory symptoms [185], and more 
importantly to memory disorders. A proposed approach is aimed towards targeting 
selectively the peripheral CB1 receptors, when the therapeutic value is related to 
receptors expressed on the periphery, thus reducing the psychoactive effects [186,187]. 
Another promising concept is the enhancement of the endocannabinoid system by 
inhibition of the hydrolysis, consequently blocking the degradation of anandamide and 
2-AG [186,188], which would potentially improve analgesia, while reducing 
side-effects. Administration of the endocannabinoid reuptake inhibitor, AM-404 inhibits 
the clearance and reuptake of ECs, therefore leads to the enhancement of the 
physiological levels of endogenously released cannabinoids, closely mimicking the 
effect of the prevention of hydrolysis. Our finding that the augmented endocannabinoid 
elevation promotes marked respiratory depression suggests a potential limitation of 
endocannabinoid reuptake and hydrolysis inhibitors in pharmacological applications 
[143].  
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7. Conclusions 
7.1. Hypersensitivity to Thromboxane Receptor Mediated Cerebral 
Vasomotion and CBF Oscillations during Acute NO-Deficiency in Rats 
The involvement of TP-receptor activation was explored in the appearance of cerebral 
blood flow oscillations under physiological conditions as well as after impaired NO 
synthesis. U-46619 elicited TP-receptor activation in control animals failed to evoke 
CBF oscillations; however, inhibition of NO-synthase by L-NAME resulted in 
increased blood pressure and reduction in CBF accompanied by oscillations in the blood 
flow that was further enhanced after TP-receptor agonist treatment. TXA2 synthesis 
inhibition with ozagrel abrogated CBF oscillations in vivo. U-46619 treatment induced 
weak contraction in isolated middle cerebral arteries, although in the absence of NO, 
sustained vasomotion could be observed that was sensitive to the Rho-kinase inhibitor, 
Y-27632. These results indicate that under pathophysiological conditions associated 
with NO-deficiency, such as subarachnoid hemorrhage, the hypersensitivity of 
TP-receptor – Rho-kinase pathway augments the development of vasomotion, 
potentially leading to the propagation of vasospasm. 
7.2. Role of Endocannabinoids and Cannabinoid-1 Receptors in 
Cerebrocortical Blood Flow Regulation 
The involvement of CB1 receptor in the cardiovascular and cerebral blood flow 
regulation was investigated under physiological conditions and during increased 
endocannabinoid levels. Inhibition of CB1 receptors under resting conditions with 
AM-251 induced no changes in the systemic or cerebral circulation, indicating that CB1 
receptor mediated mechanisms have limited influence on circulation under 
physiological conditions. During enhanced endocannabinoid activation that induced 
triphasic responses, the transient hypertension was CB1-independent; however, the 
sustained hypotension observed during phase III was sensitive to CB1 receptor 
blockade. Furthermore, the marked respiratory depression observed during phase II 
proved to be CB1-sensitive.  
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7.3. CB1 Receptor-mediated Respiratory Depression by Endocannabinoids  
The influence of increased levels of endogenously produced endocannabinoids on the 
respiratory regulation was explored; while published evidence was inadequate in 
proving undoubtedly the involvement of CB1 receptors on respiratory control. In order 
to characterize the influence of elevated EC levels on respiratory control, direct 
measurement of the respiratory parameters with pulse oximetry was used after 
enhancing endocannabinoid levels by administrating AM-404. Treatment with the 
cannabinoid reuptake inhibitor, but not with the solvent, induced transient reduction in 
respiratory rate accompanied with depression in the arterial oxygen saturation and a 
concomitant increase in breath distension in wild-type control mice. However, 
CB1-deficient mice exhibited no alterations in the measured respiratory parameters after 
AM-404 administration; indicating that the endocannabinoid system has a pivotal role 
in the physiological control of respiration by regulating the respiratory rate and 
consequently influencing arterial oxygen saturation, and this mechanism is entirely 
dependent on CB1 receptors.  
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8. Summary 
Arachidonic acid metabolites are involved in various cerebrovascular diseases 
associated with endothelial dysfunction. The aim of the present experiments was to 
investigate the role of thromboxane and endocannabinoids in the regulation of the 
cerebral circulation. To study the role of thromboxane-receptors (TP) in the regulation 
of the cerebrovascular tone, the influence of TP-receptor activation was tested both 
under physiological conditions and in the absence of NO. In our in vivo studies, TP-
receptor stimulation under baseline conditions failed to induce any changes in the 
cerebral blood flow (CBF). However, CBF oscillations, induced by pharmacological 
inhibition of NO synthase, showed further increase by TP-receptor activation and were 
severely inhibited after blockade of either TP-receptors or the Rho-kinase pathway. 
These findings implicate that the hypersensitivity of TP-receptor – Rho-kinase pathway 
contributes to the development of CBF oscillations, and may lead to vasospasms in 
pathophysiological conditions when NO availability is limited. In the second part of our 
experiments, the involvement of endocannabinoids (ECs) in cerebral blood flow 
regulation was explored. In order to model more closely the physiological distribution 
and release of ECs, a cannabinoid reuptake inhibitor was administered. Treatment with 
a CB1 receptor antagonist/inverse agonist under physiological state had no effect on 
basal circulatory and cerebrovascular parameters, indicating that CB1 receptors have 
minimal influence under resting conditions; however, enhancement of the EC system 
induced a tri-phasic response, where certain changes proved to be CB1 receptor 
mediated effects. Hypertension during phase I was resistant to CB1-inhibition, whereas 
the concomitant CBF-increase was attenuated. Conversely, the sustained hypotension 
during phase III was CB1 receptor dependent, whereas the CBF-decrease was not. 
During phase II, pronounced respiratory depression developed that was CB1 receptor 
dependent. To further elucidate the role of ECs on the physiological respiratory control, 
respiratory parameters were directly measured during EC system activation. Treatment 
with cannabinoid reuptake inhibitor elicited a transient decrease in respiration rate, a 
concomitant decrease in arterial oxygen saturation and a compensatory increase in 
breath distension. On the contrary, CB1-deficient mice showed no alterations in the 
measured respiratory parameters after EC system activation; suggesting that ECs 
influence the physiological control of respiration in a CB1 receptor dependent manner.  
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9. Összefoglalás 
Az agyi keringészavarok során kialakuló endothelialis diszfunkció az agyszövetben 
arachidonsav származékok felszabadulásához vezet. Ezen endogén vegyületcsoport agyi 
keringésre gyakorolt hatásai és a különböző cerebrovaszkuláris kórállapotok patho-
mechanizmusában játszott szerepe nem teljesen tisztázott. A felszabaduló tromboxán A2 
az agyi értónus szabályozásában betöltött szerepének alaposabb megismerése érdekében 
az aktivált tromboxán receptorok (TP) hatását vizsgáltuk élettani, valamint nitrogén-
monoxid (NO) hiányos állapotban. Élettani körülmények között a TP-receptor 
stimuláció nem volt hatással az agykéreg lokális szöveti véráramlására (CoBF), 
ellenben akut NO szintáz gátlás hatására CoBF oszcilláció jelentkezett, melyet TP-
receptor aktiváció tovább erősített és TP-receptor vagy Rho-kináz gátlás jelentősen 
gátolt. Ezen megfigyelések arra utalnak, hogy a TP-receptor - Rho-kináz útvonal 
hozzájárul a CoBF oszcillációk megjelenéséhez NO szegény kórélettani körülmények 
között, mely vazospazmus kialakulásához vezethet. Kísérleteink második csoportjában 
az endokannabinoid rendszer (EC) és a kannabinoid-1 receptorok (CB1) szisztémás- és 
agyi keringés szabályozásban játszott szerepét vizsgáltuk. Korábbi közlemények a 
kannabioidok agyi véráramlás növelő hatásáról számoltak be. Ezek a kísérletek azonban 
különböző exogén kannabinomimetikumok hatását vizsgálták, így nem feltétlenül 
reprezentálják a regionálisan eltérő koncentrációiktól függő, endogén kannabinoid 
molekulák hatásait. Nyugalmi körülmények között a CB1 receptorok gátlása nem volt 
hatással a szisztémás és CoBF paraméterekre, ellenben az EC rendszer farmakológiai 
aktivációja trifázisos válaszreakcióval járt. Az első fázis során megfigyelt hipertenzió 
CB1 független volt, ellenben a társuló CoBF emelkedés CB1 függőnek tűnt. Ezzel 
szemben a harmadik fázisban jelentkező hipotónia bizonyult CB1 függőnek, míg a 
CoBF csökkenés nem. A második fázis során erőteljes légzésdepresszió jelentkezett, 
mely hatás CB1 receptor érzékeny volt. Az endokannabinoidok fiziológiás légzés-
szabályozásban betöltött szerepét vizsgálva megállapítottuk, hogy az EC felszabadulást 
követő átmeneti légzésdepresszióhoz arteriás oxigén szaturáció csökkenés, és a légzés 
mélységének kompenzatorikus növekedése társul. Genetikailag módosított, CB1 
receptor hiányos egereken végzett kísérleteinkben ezzel szemben az EC rendszer 
aktivitásának fokozását követően nem alakult ki légzésdepresszió, arra utalva, hogy az 
EC rendszer CB1 receptorok közvetítésével befolyásolja a légzésszabályozást.  
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